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Preface
Interstitial lung diseases are rare diffuse lung diseases characterized by specific
radiological and pathohistological findings. This book is an attempt to better
understand these very specific lung diseases at the molecular level and thus under-
stand and interpret changes in the lung parenchyma and correlate with radiological 
and pathological findings and therapeutic modalities. This book also includes
information on lung transplantation as the most current approach to the treatment
of interstitial lung diseases in all stages including the end stage. A special chapter
is devoted to the physical therapy of patients with these lung diseases. This book is
intended for all doctors who deal with diagnosis and treatment of interstitial lung 
diseases, as a manual for everyday and practical literature.
I would like to thank all my colleagues who devoted their effort and time in shaping 
and writing their chapters. I wish them great success in their work.
Jelena Stojšić, MD PhD
Department of Thoracopulmonary Pathology,
Service of Pathology,
Clinical Center of Serbia,
Belgrade, Serbia
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Introductory Chapter: Diagnosis 
of Interstitial Lung Disease
Jelena Stojšić
1. Introduction
Interstitial lung diseases are rare diffuse lung disease characterized by a specific 
clinical picture and radiological (imaging) and pathohistological findings. It is 
considered that these diseases represent about 15% of all respiratory diseases [1].
Diffuse changes of the lung parenchyma in each type of these diseases are 
characterized by various morphological patterns which are reflected by a different 
imaging finding and a specific clinical picture [2–4]. The clinical picture at an early 
stage of the disease is not specific, and it is hard to suspect interstitial lung dis-
ease. Symptoms of interstitial lung disease are dry cough, short breath, fever, and 
fatigue. A specific high resolution - computed tomographyn (HR-CT)  finding indi-
cates an interstitial lung disease which is proven by biopsy. Transbronchial biopsy 
primarily excludes specific granulomatous lung diseases, primary malignancy and 
metastatic as well as eosinophilic pneumonia, alveolar proteinosis, and pulmonary 
histiocytosis. If a bioptized lung sample has nonspecific morphological pattern, 
it is necessary to perform an open lung biopsy or video-assisted thoracoscopic 
surgery (VATS). Open lung biopsy procedure requires a multidisciplinary approach 
that includes a chest surgeon. An agreement on taking large number of lung tissue 
samples characterized by change evolution increases the efficiency and accuracy of 
the diagnosis [5].
Integrated clinical and radiological data help the pathologist to establish an 
accurate diagnosis of the type of interstitial lung disease. Besides pulmonologist, 
radiologist, and pathologist, microbiologist and immunologist also participate in 
diagnostic procedure [2–4].
2.  Pathohistological diagnosis of interstitial lung disease in open lung 
biopsy
It is necessary to take the entire surgical material for processing and microscopic 
analysis. Before all, it is necessary to completely instill 10% buffered formalin 
into the lung parenchyma with a needle for injection but in a moderate amount, in 
order to not provoke artifacts in the lung parenchyma. In such a manner, alveolar 
spaces are as if they were in the air-inspiration phase, and also damages on the lung 
parenchyma caused by a forceps during biopsy performed by a surgeon are avoided. 
After fixation that lasts 24 h, the entire material is sampled into thin sections which 
are fixed in the buffered formalin, alcohol, and xylol. After that, they are embedded 
into paraffin and then cut and stained with a classical hematoxylin-eosin staining.
The pathologist at first performs microscopic examination on a low-powered-
field microscope in order to see the distribution of changes, that is, whether they are 
confluent or not. Then he observes localization of changes and their peribronchial or 
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perivascular presence or connective subpleural, interlobular, or interalveolar septa. On 
highermicrosopic microscopic field enlargements, the cellularity of changes is noted, 
as well as the type of cells that contain changes and then the presence and degree of 
fibrosis. By connective tissue staining, it is desirable to confirm the degree of fibrosis 
and with other methods to determine type of cells and presence of microorganisms. 
Immunohistochemical technique can detect the type of cells in the analyzed changes [5].
On the basis of the overall finding, descriptive diagnosis that correlates with 
the disease entity is made. Diagnosis must correlate with the clinical and imaging 
picture by the type of change. For this purpose, current classification of interstitial 
lung diseases is used [5].
The first used classification of interstitial diseases in different subtypes is 
according to Liebow and Carrington [6]. By consensus of the American Thoracic 
Society and European Respiratory Society (ATS/ERS), current classification of 
interstitial lung diseases is determined. This classification defines different clinical-
pathological entities according to clinical, radiological, and histological criteria. By 
using this classification, it is possible to predict the course of the disease, treatment, 
and outcome. Therapy and monitoring of the disease course require consultative 
decisions. The medical advisory board consists of experienced pulmonologists, 
radiologists, and pulmonary pathologists. If the course of the disease is not satisfac-
tory even with applied therapy, treatment may be evaluated, and in exceptional 
circumstances, archived tissue samples can be reexamined and diagnosis can be 
changed [1]. In addition to the therapy, in order to improve lung function which is 
tested by various functional tests, physical therapy is also desirable.
The ATS/ERS classification of these diffuse lung diseases divides them into those 
of known and those of unknown etiologies [1]. According to ATS/ERS classifica-
tion, morphological image in the lung parenchyma should correspond to clinical-
pathological diagnosis (in this part of the text, insert Table 1 from the bottom of 
the text).
Diffuse diseases of known etiology, such as connective tissue diseases or diseases 
caused by taking some drugs, are less common. Allergic alveolitis or hypersen-
sitivity pneumonitis is a specific entity of generally known etiology. Diseases of 
unknown etiology, that is, idiopathic diseases such as idiopathic lung disease, non-
specific interstitial lung disease, desquamative interstitial pneumonia, respiratory 
bronchiolitis, organized pneumonia, acute interstitial pneumonia, and lymphoid 
interstitial pneumonia, are more frequent. This group of diseases includes granulo-
matosis of which the most common is sarcoidosis characterized by the presence of 
epithelial, non-necrotizing granulomas [1].
Histological pattern Clinicopathological diagnosis
Usual interstitial pneumonia (UIP) Idiopathic pulmonary fibrosis (IPF)/cryptogenic fibrosing 
alveolitis (CFA)
Nonspecific interstitial pneumonia (NSIP) Nonspecific pneumonia
Organizing pneumonia Cryptogenic organizing pneumonia
Diffuse alveolar damage (DAD) Acute interstitial pneumonia
Desquamative interstitial pneumonia (DIP) Desquamative interstitial pneumonia
Respiratory bronchiolitis Respiratory bronchiolitis-interstitial lung disease 
(RB-ILD)
Lymphocytic interstitial pneumonia (LIP) Lymphocytic interstitial pneumonia
Table 1. 
Morphological image which corresponds to a certain clinical-pathological diagnosis according to the ATS/ERS 
classification [1].
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By using the said formulations, uniformity of the findings is achieved and 
therapy is specified. If good treatment results fail, it comes to a stage known as 
“end-stage lung disease.” In such a case, lung transplantation is proposed which 
lately requires a special chapter in each textbook about these diseases. Selection of 
the transplantation type (single, bilateral, or heart-lungs) depends on the type of 
interstitial lung disease and other factors. The success of transplantation depends 
on the type of organism reaction on the presence of the transplanted lung or the 
type of rejection which can be subacute, acute, and chronic. Changes in rejec-
tion reactions are localized around the blood vessels of the lungs or bronchi. The 
intensity of rejection reaction depends on the extent of the changes spreading in 
the pulmonary interstitium and the type of inflammatory infiltrate. Prevention and 
treatment of rejection are regulated by immunosuppressive drugs. Therefore, it is 
necessary to control the presence of microorganisms in the transplanted lung by 
microbiological tests and transbronchial biopsy [7–9].
However, the future of the treatment of interstitial lung diseases depends on the 
molecular changes in the cells found in the lesions. miRNAs profiling in lung tissue 
in various interstitial lung diseases in a variety of cells that contain lung lesions: 
endothelium, alveolar epithelium, inflammatory cells, fibroblast and myofibroblast. 
This profiling can determine the type of therapy and their outcome or success.
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Abstract
Idiopathic pulmonary fibrosis (IPF) is a genetic heterogeneous disease with 
high mortality and poor prognosis. IPF is characterized by persistent fibroblasts 
and relentless accumulation of collagen matrix. Epithelial-mesenchymal transition 
(EMT) and endothelial-to-mesenchymal transition (EndoMT) contribute to the 
progression of the fibrotic process. There are some therapeutic drugs that delay 
this progress, but eradicative medicine does not exist yet. MicroRNAs (miRNAs) 
are short single-stranded RNAs that regulate posttranscriptional silencing. Recent 
reports have shown that miRNAs play important roles in the development of IPF, 
as different expression levels of miRNAs in blood and lung tissue from IPF patients 
were closely associated with the occurrence of IPF disease. In this chapter, we will 
discuss the role of miRNAs in the pathogenesis, diagnosis, and treatment of IPF. In 
particular, we will focus on the regulation of EMT/EndoMT by miRNAs.
Keywords: IPF, miRNA, EndoMT, EMT
1. Introduction
1.1 Overview of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a genetic heterogeneous disease with 
high mortality and poor prognosis that is characterized by progressive scarring of 
the pulmonary parenchyma, which leads to progressive loss of lung function with 
dyspnea and hypoxemia, and ultimately respiratory failure and death. IPF is a 
specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown 
cause. Disease pathogenesis involves airway tissue remodeling through the excess 
deposition of extracellular matrix (ECM) proteins and the formation of fibroblastic 
foci, evident by histology [1]. These events are occurred mainly by continuous dam-
age to the lung epithelium, which destroys the basement membrane and activates 
myofibroblasts. Myofibroblasts may not only come from resident or circulating 
fibroblasts but also be brought by epithelial cells transdifferentiated through 
epithelial-mesenchymal transition (EMT) [2]. Signaling through the TGF-β path-
way is thought to underlie many of these changes [3].
According to the 2018 joint statement by the American Thoracic Society (ATS), 
European Respiratory Society (ERS), Latin America Thoracic Association (ALAT), 
and Japanese Respiratory Society (JRS) [4], the diagnosis of IPF can be secured by 
exclusion of other known causes of interstitial lung disease (ILD) and either the 
4
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presence of high resolution computed tomography (HRCT) pattern of usual inter-
stitial pneumonia (UIP) or specific combinations of HRCT patterns and histopa-
thology patterns in patients subjected to lung tissue sampling. Any plausible cause 
of secondary interstitial involvement should be excluded by a thorough medical his-
tory and other procedures such as laboratory tests or bronchoalveolar lavage (BAL) 
when necessary. If a specific diagnosis is not made or no potential cause for ILD is 
identified, then clinical findings and HRCT are considered during multidisciplinary 
discussion among different experts (including clinicians, radiologists, pathologists, 
rheumatologists, and thoracic surgeons in selected cases) [4].
1.2 Overview of miRNAs
MicroRNAs (miRNAs) are short single-stranded RNA molecules of 19–25 
nucleotides in length that mediate posttranscriptional gene silencing of target genes 
[5]. MiRNAs have been recognized as a distinct class of small regulatory RNAs in 
multiple species that regulate a wide variety of functions such as cell proliferation, 
differentiation, apoptosis, stress response, and immune response [6–8]. MiRNAs 
regulate the onset and progress of a variety of diseases, such as cancer, infections, 
and atherosclerosis [9–11]. In lung diseases, many miRNAs contribute to the patho-
genesis. For instance, miR-424/503 regulates the progression of pulmonary hyper-
tension (PH) [12, 13]. miR-424/503 expression is reduced in the pulmonary artery 
of PH patients [13]. One of the targets of miR-424/503 is Rictor, and inhibition of 
miR-424/503 expression increased the expression of Rictor, leading to endothelial-
to-mesenchymal transition (EndoMT) and migration of pulmonary artery endo-
thelial cells [12]. In allergic asthma, miR-21, miR-126, and miR-145 are upregulated 
in multiple experimental asthma models [14–16], and miR-221 and miR-485-3p are 
upregulated in the peripheral blood of pediatric patients with asthma, compared 
with controls [17].
2. IPF and miRNAs
Profiling of miRNAs in the lung tissue from IPF patients was performed by 
different groups [18–22]. In IPF lungs, the expression of miR-21 and miR-155 was 
increased, whereas the expression of let-7a, miR-29, miR-30, and miR-101 was 
decreased [23–25]. MiR-21 expression was increased in the serum of IPF patients, 
and its levels correlated with a decrease in lung function [26]. In the miRNA expres-
sion profiling of sputum-derived exosomes from IPF patients, 21 miRNAs were dif-
ferentially expressed, among which seven (e.g., miR-142-3p and miR-33a-5p) were 
upregulated and 14 (e.g., Let-7d-5p) were downregulated [27]. In bronchoalveolar 
lavage fluid (BALF), miR-29a and miR-185 are downregulated in IPF patients [28, 29]. 
However, little is known about miRNA functions in IPF; much of the functional 
data has been inferred from chemically induced mouse IPF models. In the lungs of 
mouse IPF models, miR-21, miR-9, and miR-155 were increased [19, 21, 30], and 
miR-26, miR-101, miR-139, miR-200, miR-326, miR-489, miR-503, and miR-708 
were decreased [24, 31–37]. Furthermore, miR-21 expression was increased in 
myofibroblasts from IPF lungs, and its inhibition in mouse IPF models attenuated 
the disease severity [19]. The expression of miR-200 family members was reduced 
in mouse IPF models and restoration of miR-200c inhibited fibrosis [33]. Similarly, 
miR-26a was decreased in mouse IPF models and its inhibition caused pulmonary 
fibrosis, while overexpression repressed fibrotic disease [38]. Finally, miR-326 was 
decreased in mouse IPF models, and its administration mimicked inhibited TGF-β 
expression and attenuated fibrosis [34].
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3. The role of miRNAs in IPF-contributing cells
Epithelial cells communicate each other via adhesion molecules under physio-
logical condition. Among many adhesion molecules, E-cadherin plays an important 
role in maintaining tight junctions of epithelial cells. Recurrent and nonresolving 
injury to lung epithelial cells appears to be a key driver of pulmonary fibrosis. 
Recent studies have supported the concept that altered alveolar epithelial cell 
phenotypes, including those produced by increased endoplasmic reticulum stress, 
predispose to further epithelial cell injury and abnormal repair, facilitating the 
development of pulmonary fibrosis [39, 40], and thus suggested that the epithelial 
abnormalities/dysfunction underlying fibrosis should be referred to as reprogram-
ming. The ability of epithelial cells to change into mesenchymal cells through EMT 
plays an important role in the development of IPF.
Myofibroblasts and related mesenchymal cells are generally accepted as the cells 
predominantly responsible for fibrotic destruction/distortion of the lung in IPF 
[41]. Proliferation of fibroblasts and their differentiation into myofibroblasts are 
important in the development of IPF. The stage of mesenchymal cell differentia-
tion at which IPF myofibroblasts acquire hallmark pathological properties, the 
mechanisms underlying their pathological differentiation, and the roles of signals 
from epithelial cells, immune cells, and the matrix in this process has not been fully 
elucidated and requires further research.
The lung extracellular matrix (ECM) is comprised of collagens, elastin, 
glycoproteins, and proteoglycans, which serve as structural scaffolding for cells 
and provide the mechanical stability and elastic recoil necessary for proper lung 
function. In normal wound healing, myofibroblasts that produce ECM proteins are 
recruited during the active phase of repair, but are quickly removed via apoptosis 
once the repair process is underway. Most of the scar matrix subsequently resolves 
and is replaced by a more permanent tissue. In IPF, myofibroblasts are relatively 
resistant to apoptosis, and their persistence leads to excessive scarring [42]. A 
hallmark of IPF is the accumulation of myofibroblasts in clusters called fibroblastic 
foci and extensive ECM deposition within the interstitium, resulting in destruction 
of alveolar architecture.
Vascular muscularization driven by repeated small injury is the main patho-
genesis of PH, leading to the sustained fibrotic process of intima [43]. Different 
cellular processes have been described during pulmonary artery remodeling of 
PH-associated IPF, including endothelial dysfunction [44], EndoMT as a source of 
myofibroblasts [45], and pulmonary artery smooth muscle proliferation [46].
Monocytes and macrophages have a key role in regulating tissue repair 
and fibrosis, and several molecular pathways regulating their activity are 
being investigated as potential treatments for IPF. Macrophages possess many 
functions that would be expected to promote fibrosis, including fibroblast 
proliferation [47], regulation of ECM components [48], and secretion of pro-
fibrotic cytokines and growth factors. However, macrophages may also possess 
antifibrotic properties [47, 49]. Several studies have attributed these opposing 
functions to different macrophage populations distinguished along the lines of 
classical (M1) and alternative (M2) macrophage activation [50–52], with M1 
macrophages being antifibrotic and M2 macrophages being either profibrotic or 
regulatory.
Adaptive immune responses are involved in the pathological process in IPF 
patients. Infiltration of activated CD4+ T-cells into IPF lung is often observed 
before symptoms are developed [53]. Mature dendritic cells also infiltrate in the 
pulmonary parenchyma of IPF patients [54]. FoxP3 positive regulatory T-cells are 
diminished in both the circulation and BALF of IPF patients [55].
Interstitial Lung Diseases
6
presence of high resolution computed tomography (HRCT) pattern of usual inter-
stitial pneumonia (UIP) or specific combinations of HRCT patterns and histopa-
thology patterns in patients subjected to lung tissue sampling. Any plausible cause 
of secondary interstitial involvement should be excluded by a thorough medical his-
tory and other procedures such as laboratory tests or bronchoalveolar lavage (BAL) 
when necessary. If a specific diagnosis is not made or no potential cause for ILD is 
identified, then clinical findings and HRCT are considered during multidisciplinary 
discussion among different experts (including clinicians, radiologists, pathologists, 
rheumatologists, and thoracic surgeons in selected cases) [4].
1.2 Overview of miRNAs
MicroRNAs (miRNAs) are short single-stranded RNA molecules of 19–25 
nucleotides in length that mediate posttranscriptional gene silencing of target genes 
[5]. MiRNAs have been recognized as a distinct class of small regulatory RNAs in 
multiple species that regulate a wide variety of functions such as cell proliferation, 
differentiation, apoptosis, stress response, and immune response [6–8]. MiRNAs 
regulate the onset and progress of a variety of diseases, such as cancer, infections, 
and atherosclerosis [9–11]. In lung diseases, many miRNAs contribute to the patho-
genesis. For instance, miR-424/503 regulates the progression of pulmonary hyper-
tension (PH) [12, 13]. miR-424/503 expression is reduced in the pulmonary artery 
of PH patients [13]. One of the targets of miR-424/503 is Rictor, and inhibition of 
miR-424/503 expression increased the expression of Rictor, leading to endothelial-
to-mesenchymal transition (EndoMT) and migration of pulmonary artery endo-
thelial cells [12]. In allergic asthma, miR-21, miR-126, and miR-145 are upregulated 
in multiple experimental asthma models [14–16], and miR-221 and miR-485-3p are 
upregulated in the peripheral blood of pediatric patients with asthma, compared 
with controls [17].
2. IPF and miRNAs
Profiling of miRNAs in the lung tissue from IPF patients was performed by 
different groups [18–22]. In IPF lungs, the expression of miR-21 and miR-155 was 
increased, whereas the expression of let-7a, miR-29, miR-30, and miR-101 was 
decreased [23–25]. MiR-21 expression was increased in the serum of IPF patients, 
and its levels correlated with a decrease in lung function [26]. In the miRNA expres-
sion profiling of sputum-derived exosomes from IPF patients, 21 miRNAs were dif-
ferentially expressed, among which seven (e.g., miR-142-3p and miR-33a-5p) were 
upregulated and 14 (e.g., Let-7d-5p) were downregulated [27]. In bronchoalveolar 
lavage fluid (BALF), miR-29a and miR-185 are downregulated in IPF patients [28, 29]. 
However, little is known about miRNA functions in IPF; much of the functional 
data has been inferred from chemically induced mouse IPF models. In the lungs of 
mouse IPF models, miR-21, miR-9, and miR-155 were increased [19, 21, 30], and 
miR-26, miR-101, miR-139, miR-200, miR-326, miR-489, miR-503, and miR-708 
were decreased [24, 31–37]. Furthermore, miR-21 expression was increased in 
myofibroblasts from IPF lungs, and its inhibition in mouse IPF models attenuated 
the disease severity [19]. The expression of miR-200 family members was reduced 
in mouse IPF models and restoration of miR-200c inhibited fibrosis [33]. Similarly, 
miR-26a was decreased in mouse IPF models and its inhibition caused pulmonary 
fibrosis, while overexpression repressed fibrotic disease [38]. Finally, miR-326 was 
decreased in mouse IPF models, and its administration mimicked inhibited TGF-β 
expression and attenuated fibrosis [34].
7
The Role of miRNAs in Idiopathic Pulmonary Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.82771
3. The role of miRNAs in IPF-contributing cells
Epithelial cells communicate each other via adhesion molecules under physio-
logical condition. Among many adhesion molecules, E-cadherin plays an important 
role in maintaining tight junctions of epithelial cells. Recurrent and nonresolving 
injury to lung epithelial cells appears to be a key driver of pulmonary fibrosis. 
Recent studies have supported the concept that altered alveolar epithelial cell 
phenotypes, including those produced by increased endoplasmic reticulum stress, 
predispose to further epithelial cell injury and abnormal repair, facilitating the 
development of pulmonary fibrosis [39, 40], and thus suggested that the epithelial 
abnormalities/dysfunction underlying fibrosis should be referred to as reprogram-
ming. The ability of epithelial cells to change into mesenchymal cells through EMT 
plays an important role in the development of IPF.
Myofibroblasts and related mesenchymal cells are generally accepted as the cells 
predominantly responsible for fibrotic destruction/distortion of the lung in IPF 
[41]. Proliferation of fibroblasts and their differentiation into myofibroblasts are 
important in the development of IPF. The stage of mesenchymal cell differentia-
tion at which IPF myofibroblasts acquire hallmark pathological properties, the 
mechanisms underlying their pathological differentiation, and the roles of signals 
from epithelial cells, immune cells, and the matrix in this process has not been fully 
elucidated and requires further research.
The lung extracellular matrix (ECM) is comprised of collagens, elastin, 
glycoproteins, and proteoglycans, which serve as structural scaffolding for cells 
and provide the mechanical stability and elastic recoil necessary for proper lung 
function. In normal wound healing, myofibroblasts that produce ECM proteins are 
recruited during the active phase of repair, but are quickly removed via apoptosis 
once the repair process is underway. Most of the scar matrix subsequently resolves 
and is replaced by a more permanent tissue. In IPF, myofibroblasts are relatively 
resistant to apoptosis, and their persistence leads to excessive scarring [42]. A 
hallmark of IPF is the accumulation of myofibroblasts in clusters called fibroblastic 
foci and extensive ECM deposition within the interstitium, resulting in destruction 
of alveolar architecture.
Vascular muscularization driven by repeated small injury is the main patho-
genesis of PH, leading to the sustained fibrotic process of intima [43]. Different 
cellular processes have been described during pulmonary artery remodeling of 
PH-associated IPF, including endothelial dysfunction [44], EndoMT as a source of 
myofibroblasts [45], and pulmonary artery smooth muscle proliferation [46].
Monocytes and macrophages have a key role in regulating tissue repair 
and fibrosis, and several molecular pathways regulating their activity are 
being investigated as potential treatments for IPF. Macrophages possess many 
functions that would be expected to promote fibrosis, including fibroblast 
proliferation [47], regulation of ECM components [48], and secretion of pro-
fibrotic cytokines and growth factors. However, macrophages may also possess 
antifibrotic properties [47, 49]. Several studies have attributed these opposing 
functions to different macrophage populations distinguished along the lines of 
classical (M1) and alternative (M2) macrophage activation [50–52], with M1 
macrophages being antifibrotic and M2 macrophages being either profibrotic or 
regulatory.
Adaptive immune responses are involved in the pathological process in IPF 
patients. Infiltration of activated CD4+ T-cells into IPF lung is often observed 
before symptoms are developed [53]. Mature dendritic cells also infiltrate in the 
pulmonary parenchyma of IPF patients [54]. FoxP3 positive regulatory T-cells are 
diminished in both the circulation and BALF of IPF patients [55].
Interstitial Lung Diseases
8
3.1 Alveolar epithelial cells
miRNA microarray analysis of lung tissue from healthy controls and IPF patients 
showed that the expression of several let-7 family members was lower in IPF patients 
[18]. The human let-7 family includes 12 members (let-7-a1, a2, a3, b, c, d, e, f1, f2, 
g, 1, and miR-98), located on eight different homologous chromosomes [56]. In vitro 
inhibition of let-7d induced an increase in mesenchymal markers in lung epithelial 
cell lines. The High Mobility Group A2 (HMGA2) 3′ UTR has seven conserved sites 
complementary to the let-7 miRNA [57], and HMGA2 was significantly overex-
pressed in IPF lungs compared with controls [58]. In lung epithelial cell lines, let-7d 
regulated HMGA2 expression, and the increase in HMGA2 after TGF-β stimulation 
depended on inhibition of let-7 [18]. HMGA2 facilitates the transcription of SNAI1 
and TWIST, the transcriptional repressors of adherens, which are tight and desmo-
somal junction components, leading to reduced intracellular adhesion. Moreover, it 
is a mediator of TGF-β-induced EMT. Downregulation of let-7d also led to upregula-
tion of other fibrosis-relevant targets, such as RAS, insulin-like growth factor-1 
(IGF-1), and IGF-1 receptor, and thus to the profound and sustained changes in 
cellular phenotype that are indeed observed in IPF [18] (Figure 1).
The expression of miR-26a was significantly decreased in the lungs of mice 
following the administration of bleomycin [59]. Alignment of miR-26a with the 
HMGA2 3′UTR sequence revealed one potential conserved seed site. Transient 
introduction of miR-26a into A549 cells, a pulmonary epithelial cell line, led to a 
significant decrease in HMGA2. However, the reduction in miR-26a expression 
induced an obvious EMT phenotype in A549 cells together with a clear alteration in 
certain related proteins, including E-cadherin, vimentin, and α-SMA [59]. Loss of 
function of miR-26a facilitated lung epithelial cells to transform into myofibroblasts 
and induce pulmonary fibrosis in mice. Lin28D is also one of the conserved putative 
target genes of miR-26a. Inhibition of miR-26a induced Lin28D expression and 
caused an obvious EMT phenotype in A549 cells [31].
Figure 1. 
The role of miRNAs in alveolar epithelial cells for IPF.
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The miR-200 family has been suggested to regulate the progression of pulmo-
nary fibrosis by suppressing the EMT of alveolar epithelial cells (AECs). MiR-200 
family members correlated with E-cadherin expression in epithelial cells [60, 61] 
and negatively correlated with ZEB family expression, which has been implicated in 
EMT [62]. Furthermore, the miR-200 family members have been identified as EMT 
suppressors through direct targeting of ZEB1 and ZEB2 [63]. MiR-200 is downregu-
lated in the lungs of IPF patients and mouse IPF models [33]. In AECs, overexpres-
sion of miR-200, particularly miR-200b and miR-200c, attenuated TGF-β1-induced 
mesenchymal cell morphological characteristics and TGF-β1-repressed E-cadherin 
expression [33].
In fibrotic lungs, TGF-β1 is overexpressed in a broad range of cells, including 
epithelial cells, leading to the dysregulation of normal lung homeostasis by increas-
ing the synthesis and altering the balance of matrix metalloproteinases and their 
inhibitors [64]. MiR-326 targets the TGF-β1 3′UTR, and miR-326 levels inversely 
correlate with TGF-β1 protein levels in multiple human cell lines and in the lungs 
of mouse IPF models [34]. Restoration of miR-326 levels by intranasal delivery 
of miR-326 mimics was sufficient to inhibit TGF-β1 expression and attenuate the 
fibrotic response in the lungs of mouse IPF models [34]. Furthermore, miR-1343 
targets the 3′UTRs of TGFBR1 and TGFBR2 and attenuates EMT and fibrogenesis 
by inhibiting the TGF-β1 pathway in alveolar epithelial cell lines [65].
3.2 Fibroblasts and myofibroblasts
Several studies have shown that some miRNAs including miR-21, miR-29, miR-
101, miR-153, miR-154, miR-155, and miR-210 regulate the function of fibroblasts 
in the lungs (Figure 2).
The expression of miR-21 is increased in the lungs of mouse IPF models and 
of patients with IPF [19]. In mouse IPF models, miR-21 inhibition by lentiviruses 
encoding anti-miR-21 suppressed morphological markers of pulmonary fibrosis 
compared with controls [23]. TGF-β1 is the most important profibrogenic cytokine, 
which increases the expression of miR-21 through SMAD2/3/4 in lung fibroblasts 
[19] [66]. MiR-21 inhibition inversely regulates TGF-β1-induced ECM protein 
expression in human pulmonary fibroblast cell lines [23]. Smad7, which inhibits the 
proliferation of interstitial fibroblasts, is a direct target of miR-21 and negatively 
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Members of the miR-29 family, which consists of three mature members, 
miR-29a, miR-29b, and miR-29c, are among the most downregulated miRNAs in 
IPF lungs [66]. The expression of miR-29c is also decreased in the lungs of mouse 
IPF models [67]. MiR-29 has many target genes involved in the composition and 
regulation of ECM, thus downregulation of miR-29 is capable of contributing to 
excessive ECM deposition [20, 68]. In human fetal lung fibroblasts, miR-29 sup-
pression upregulated a series of genes, such as TGF-β1 regulated genes and adhesion 
molecules associated with the fibrotic phenotype [18].
MiR-101 is also one of the most downregulated miRNAs in fibrotic lungs from 
IPF patients and mouse IPF models [24]. Hypoxia-inducible factors (HIFs) con-
tribute to the pathogenesis of pulmonary fibrosis through Nuclear Factor-Activated 
T-cell (NFAT) c2 [69]. MiR-101 suppressed WNT5a-induced proliferation of lung 
fibroblasts via inhibition of NFATc2 signaling by targeting Frizzled receptor 4/6 
and attenuated bleomycin-induced pulmonary fibrosis in mouse IPF models [24].
MiR-153 is an intragenic miRNA that is embedded in genes encoding islet-asso-
ciated protein (IA)-2 and 2β. It has been shown to participate in the pathogenesis of 
neurodegenerative diseases [70] and inhibit the proliferation and invasion of many 
types of malignant cells [71]. Furthermore, TGF-β1 downregulates miR-153 expres-
sion in lung fibrosis, and miR-153 was downregulated in the fibrotic phase, which 
was characterized by excessive proliferation of fibroblasts and deposition of ECM 
in mouse IPF models [72]. However, miR-153 reduced the contractile and migratory 
activities of fibroblasts. TGFBR2, a transmembrane serine/threonine kinase recep-
tor for TGF-β, has been identified as a direct target of miR-153; moreover, miR-375 
regulates SMAD2/3 phosphorylation and the fibrogenic activity of lung fibroblasts 
through TGFBR2 inhibition [72].
The majority of increased miRNAs in IPF localizes to chromosome 14q32 and 
is enriched with members of the miR-154 family. TGF-β1 regulates the expression 
of miRNAs in the 14q32 cluster and induces the expression changes similar to those 
seen in IPF. TGF-β1 induces cell proliferation through CDK4 and CDKN2B, a CDK4 
inhibitor, which is a miR-154 target. Furthermore, TGF-β1-induced increases in 
proliferation were significantly reduced in the presence of miR-154 inhibitor in 
fibroblasts, and miR-154-induced changes in proliferation were mediated through 
the activation of the WNT/β-catenin pathway in fibroblasts [73].
MiR-155 is required for normal immune function [74]. Its overexpression is associ-
ated with inflammation, autoimmunity, and cancer [75], whereas miR-155-deficient 
mice develop age-related airway fibrosis [76]. Liver X receptor alpha (LXRα), which 
is an oxysterol-activated transcription factor, has a conserved 3′UTR seed-region 
sequence complementary to miR-155, and inhibition of LXRα ameliorated lung 
fibrosis in miR-155-deficient mice [77]. However, enforced expression of miR-155 
reduced the profibrotic phenotype of IPF and miR-155-deficient fibroblasts [77]. 
Thus, miR-155 attenuates lung fibrosis through inhibition of LXRα in lung fibroblasts.
The expression of miR-210 has been found to be increased in patients with 
rapidly progressive IPF, who typically have experienced hypoxia [22]. Consistently, 
miR-210 was upregulated in IPF fibroblasts in response to hypoxia, and its 
knockdown suppressed the hypoxia-induced proliferation of IPF fibroblasts. 
Furthermore, HIF-2α regulated miR-210 expression and miR-210-mediated pro-
liferation of IPF fibroblasts in response to hypoxia. Finally, miR-210 promoted IPF 
fibroblast proliferation through repression of its downstream target, MNT [78].
3.3 Endothelial cells
PH is frequently seen in IPF patients and is commonly attributed to hypoxic 
vasoconstriction and capillary destruction. Pathology findings include endothelial 
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proliferation and medial hypertrophy that exceed those expected in the setting 
of hypoxia [79] (Figure 3). HIF-1 activates the transcription of genes encoding 
angiogenic growth factors, including vascular endothelial growth factor (VEGF), 
angiopoietin (ANGPT), placental growth factor (PGF), and platelet-derived 
growth factor (PDGF), which are secreted by hypoxic cells and stimulate endothe-
lial cells, leading to angiogenesis. Furthermore, HIF-1 mediates hypoxia-induced 
phenotypic changes typical of EndoMT in endothelial cells [80].
ANGPT1 is a ligand for receptor tyrosine kinase Tie2 [81], which is expressed 
in endothelial cells [82]. ANGPT1-Tie2 signaling has been shown to be involved 
mainly in angiogenic activity and promoting maturation of blood vessels, and it 
is regulated by Akt and MAPK signaling [83, 84]. The activation of ANGPT1-Tie2 
signaling correlates with the severity of PH [85]. Mir-34a is downregulated in rat 
pulmonary arterial hypertension models [86], and ANGPT1 and Tie2 are potential 
targets of miR-34a, as they have a conserved miR-34a seed sequence in their 3′UTR 
[87]. Overexpression of miR-34a also downregulated the expression of PDGFRA, 
one of therapeutic targets of IPF, in pulmonary artery smooth muscle cells [86].
EndoMT has been proposed to be another potential source of myofibroblasts. 
In EndoMT, endothelial cells lose their own markers and obtain mesenchymal 
phenotype. Silencing of miR-155 directly increased RhoA expression and activ-
ity in endothelial cells and affected phosphorylation of the downstream LMK. A 
selective Rho kinase inhibitor partly suppressed EndoMT, strengthening the notion 
that RhoA plays a central role in EndoMT. Overexpression of miR-155 suppressed 
EndoMT, hence miR-155 functions as a negative regulator of RhoA signaling in 
TGF-β-induced EndoMT [88]. EndoMT has been considered as a source of myofi-
broblasts in PH [45], and miR-155 is downregulated in IPF lungs. Thus, miR-155 has 
been suggested to affect PH-associated IPF through inducing EndoMT.
3.4 Inflammatory cells
Macrophages possess many functions that would be expected to promote 
fibrosis, including regulation of fibroblast proliferation, recruitment, and activa-
tion, direct regulation of ECM components, and secretion of profibrotic cytokines 
and growth factors. There are two opposite characteristic types of functional 
macrophages; pro-inflammatory (M1) macrophages induced by toll-like receptor 
(TLR) and T helper type 1 (Th1) signals and anti-inflammatory (M2) macrophages 
Figure 3. 
The role of miRNAs in pulmonary endothelial cells for IPF.
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excessive ECM deposition [20, 68]. In human fetal lung fibroblasts, miR-29 sup-
pression upregulated a series of genes, such as TGF-β1 regulated genes and adhesion 
molecules associated with the fibrotic phenotype [18].
MiR-101 is also one of the most downregulated miRNAs in fibrotic lungs from 
IPF patients and mouse IPF models [24]. Hypoxia-inducible factors (HIFs) con-
tribute to the pathogenesis of pulmonary fibrosis through Nuclear Factor-Activated 
T-cell (NFAT) c2 [69]. MiR-101 suppressed WNT5a-induced proliferation of lung 
fibroblasts via inhibition of NFATc2 signaling by targeting Frizzled receptor 4/6 
and attenuated bleomycin-induced pulmonary fibrosis in mouse IPF models [24].
MiR-153 is an intragenic miRNA that is embedded in genes encoding islet-asso-
ciated protein (IA)-2 and 2β. It has been shown to participate in the pathogenesis of 
neurodegenerative diseases [70] and inhibit the proliferation and invasion of many 
types of malignant cells [71]. Furthermore, TGF-β1 downregulates miR-153 expres-
sion in lung fibrosis, and miR-153 was downregulated in the fibrotic phase, which 
was characterized by excessive proliferation of fibroblasts and deposition of ECM 
in mouse IPF models [72]. However, miR-153 reduced the contractile and migratory 
activities of fibroblasts. TGFBR2, a transmembrane serine/threonine kinase recep-
tor for TGF-β, has been identified as a direct target of miR-153; moreover, miR-375 
regulates SMAD2/3 phosphorylation and the fibrogenic activity of lung fibroblasts 
through TGFBR2 inhibition [72].
The majority of increased miRNAs in IPF localizes to chromosome 14q32 and 
is enriched with members of the miR-154 family. TGF-β1 regulates the expression 
of miRNAs in the 14q32 cluster and induces the expression changes similar to those 
seen in IPF. TGF-β1 induces cell proliferation through CDK4 and CDKN2B, a CDK4 
inhibitor, which is a miR-154 target. Furthermore, TGF-β1-induced increases in 
proliferation were significantly reduced in the presence of miR-154 inhibitor in 
fibroblasts, and miR-154-induced changes in proliferation were mediated through 
the activation of the WNT/β-catenin pathway in fibroblasts [73].
MiR-155 is required for normal immune function [74]. Its overexpression is associ-
ated with inflammation, autoimmunity, and cancer [75], whereas miR-155-deficient 
mice develop age-related airway fibrosis [76]. Liver X receptor alpha (LXRα), which 
is an oxysterol-activated transcription factor, has a conserved 3′UTR seed-region 
sequence complementary to miR-155, and inhibition of LXRα ameliorated lung 
fibrosis in miR-155-deficient mice [77]. However, enforced expression of miR-155 
reduced the profibrotic phenotype of IPF and miR-155-deficient fibroblasts [77]. 
Thus, miR-155 attenuates lung fibrosis through inhibition of LXRα in lung fibroblasts.
The expression of miR-210 has been found to be increased in patients with 
rapidly progressive IPF, who typically have experienced hypoxia [22]. Consistently, 
miR-210 was upregulated in IPF fibroblasts in response to hypoxia, and its 
knockdown suppressed the hypoxia-induced proliferation of IPF fibroblasts. 
Furthermore, HIF-2α regulated miR-210 expression and miR-210-mediated pro-
liferation of IPF fibroblasts in response to hypoxia. Finally, miR-210 promoted IPF 
fibroblast proliferation through repression of its downstream target, MNT [78].
3.3 Endothelial cells
PH is frequently seen in IPF patients and is commonly attributed to hypoxic 
vasoconstriction and capillary destruction. Pathology findings include endothelial 
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proliferation and medial hypertrophy that exceed those expected in the setting 
of hypoxia [79] (Figure 3). HIF-1 activates the transcription of genes encoding 
angiogenic growth factors, including vascular endothelial growth factor (VEGF), 
angiopoietin (ANGPT), placental growth factor (PGF), and platelet-derived 
growth factor (PDGF), which are secreted by hypoxic cells and stimulate endothe-
lial cells, leading to angiogenesis. Furthermore, HIF-1 mediates hypoxia-induced 
phenotypic changes typical of EndoMT in endothelial cells [80].
ANGPT1 is a ligand for receptor tyrosine kinase Tie2 [81], which is expressed 
in endothelial cells [82]. ANGPT1-Tie2 signaling has been shown to be involved 
mainly in angiogenic activity and promoting maturation of blood vessels, and it 
is regulated by Akt and MAPK signaling [83, 84]. The activation of ANGPT1-Tie2 
signaling correlates with the severity of PH [85]. Mir-34a is downregulated in rat 
pulmonary arterial hypertension models [86], and ANGPT1 and Tie2 are potential 
targets of miR-34a, as they have a conserved miR-34a seed sequence in their 3′UTR 
[87]. Overexpression of miR-34a also downregulated the expression of PDGFRA, 
one of therapeutic targets of IPF, in pulmonary artery smooth muscle cells [86].
EndoMT has been proposed to be another potential source of myofibroblasts. 
In EndoMT, endothelial cells lose their own markers and obtain mesenchymal 
phenotype. Silencing of miR-155 directly increased RhoA expression and activ-
ity in endothelial cells and affected phosphorylation of the downstream LMK. A 
selective Rho kinase inhibitor partly suppressed EndoMT, strengthening the notion 
that RhoA plays a central role in EndoMT. Overexpression of miR-155 suppressed 
EndoMT, hence miR-155 functions as a negative regulator of RhoA signaling in 
TGF-β-induced EndoMT [88]. EndoMT has been considered as a source of myofi-
broblasts in PH [45], and miR-155 is downregulated in IPF lungs. Thus, miR-155 has 
been suggested to affect PH-associated IPF through inducing EndoMT.
3.4 Inflammatory cells
Macrophages possess many functions that would be expected to promote 
fibrosis, including regulation of fibroblast proliferation, recruitment, and activa-
tion, direct regulation of ECM components, and secretion of profibrotic cytokines 
and growth factors. There are two opposite characteristic types of functional 
macrophages; pro-inflammatory (M1) macrophages induced by toll-like receptor 
(TLR) and T helper type 1 (Th1) signals and anti-inflammatory (M2) macrophages 
Figure 3. 
The role of miRNAs in pulmonary endothelial cells for IPF.
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activated by Th2 signals [89] [90]. Th2 cytokines, IL-4 and IL-13 (IL-4/IL-13), con-
tribute to extensive tissue fibrosis in mouse models [91], and IL-4/IL-13-induced 
macrophages activate fibroblasts by secreting pro-fibrogenic cytokines. IL-4/IL-13 
induced CCL18 in lung macrophages of IPF patients, and secreted CCL18 increased 
the production of collagen from fibroblasts [92]. Many transcriptional factors, such 
as STAT (signal transducers and activator of transcription) family, regulate macro-
phage polarization. M1 macrophage polarization is controlled via STAT1, and M2 
macrophages activation is mediated by STAT6 [93]. To maintain STAT6 phosphory-
lation, M2 macrophages overcome strong expression of suppressor of cytokine 
signaling 1 (SOCS1), resulting in the prolongation of fibrogenesis (Figure 4).
IL-4/IL-13 induced miR-142-5p expression and suppressed miR-130a-3p expres-
sion in macrophages [94]. Transfection of macrophages with either miR-142-5p 
anti-sense oligonucleotides or miR-130-3p mimics significantly reduced the expres-
sion of M2 markers induced by IL-4 and regulated macrophage pro-fibrogenesis 
[94]. SOCS1 3′UTR has seven conserved sites complementary to miR-142-5p RNA, 
and PPARγ 3′UTR has seven conserved sites complementary to miR-130a-3p 
RNA. The expression of SOCS1 is reduced in IPF lungs, and bleomycin-induced 
lung fibrosis and inflammation were enhanced in SOCS1-deficient mice compared 
with WT mice [95]. Thus, miR-142-5p and miR-130a-3p regulate pulmonary 
fibrosis through SOCS1 and PPARγ in macrophages.
Downregulation of miR-185 has been demonstrated in IPF lung tissue and 
alveolar macrophages [29, 96]. MiR-185 inhibited cell growth and proliferation by 
directly targeting AKT1 [97]. Downregulation of miR-185 resulted in AKT activa-
tion via increased DNMT1 expression, leading to promoter hypermethylation 
and silencing of PTEN [77]. Moreover, miR-185 directly bound and degraded the 
3′UTR of AKT1 mRNA [98]. Finally, TGF-β1 inhibited the expression of miR-185 in 
macrophages, and thus TGF-β1 signaling has been suggested to induce proliferation 
and activation of macrophages through inhibition of miR-185 expression [98].
Some lymphocytic cytokines are considered profibrotic with direct effects on 
fibroblast and myofibroblast activity in IPF. Th1, Th2, and Th17 have been linked 
to IPF pathogenesis. The Th1 subset produces IL-1α, TNF-α, PDGF, and TGF-β1. 
The Th2 subset typical interleukins are IL-4 and IL-13, which are directly involved 
in fibroblast activation and ECM production. The Th17 subset indirectly promotes 
fibrosis by increasing TGF-β1 levels, and it is positively regulated by TGF-β1, 
Figure 4. 
The role of miRNAs in macrophages for IPF.
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creating a positive feedback loop [99]. In both BALF and the peripheral blood of 
IPF patients, the number of CD4 + CD25 + FOXP3+ regulatory T-cells (Tregs) is 
decreased compared with healthy people. Thus, Tregs’ numerical and functional 
deficiency may play a central role in the initial phases of IPF pathogenesis [55].
In CD4+ T cells, the level of miR-155 expression is positively associated with the 
expression of the Th2 cytokines, IL-5 and IL-13, and miR-155 suppresses inhibitors 
of cytokine production including SOCS1 [100]. However, Foxp3 inhibition signifi-
cantly decreased miR-146a expression in Tregs. The target gene of miR-146a is TNF 
receptor-associated factor 6 (TRAF6). Foxp3 and miR-146a have been suggested to 
regulate colonic inflammation and fibrosis by negatively regulating TRAF6 [101].
4. Conclusions
IPF is a heterogeneous disease that is affected and developed by various genetic 
backgrounds and environments. The recent development and approval of antifi-
brotic agents such as nintedanib and pirfenidone, both of which reduced the lung 
function decline rate in IPF patients in clinical trials, offer hope that it may be 
possible to alter the increased mortality associated with IPF; however, these thera-
peutic effects are not sufficient for curing the disease. To reveal new therapeutic 
IPF targets, genetic screening of IPF patients, including miRNAs, is an effective 
option. Over the past decade, the role of miRNAs in both promoting and alleviating 
chronic respiratory disease has become increasingly apparent. In IPF, some miRNAs 
have been indicated to be associated with EMT, EndoMT, fibrocyte differentiation, 
or ECM deposition. Investigation of miRNAs and their target genes associated 
with IPF may lead to new therapy. However, there have been some problems with 
applying miRNAs in the clinical scene: (1) multiple groups performing studies 
with similar experimental conditions have reported different and often contrasting 
results. Hence, collection methods and specimen parts need to be standardized, 
and better assays are needed for high-confidence miRNA measurements. (2) It is 
not clear whether miRNA misregulation is a direct cause of disease or an indirect 
result of gene regulatory processes. Most studies did not attempt to establish the 
necessity and sufficiency of the miRNA under investigation. (3) It is still difficult 
to interfere with miRNA expression in the human body, and it is possible that such 
interference will cause unexpected adverse reactions. (4) It has not been established 
how to introduce miRNAs into target cells safely and effectively, and the cost of this 
treatment will probably be high. Thus, miRNAs are still insufficient to be used as 
therapeutic targets in the clinical scene. Nevertheless, miRNAs may be important 
tools as IPF biomarkers. To use miRNAs clinically, further studies are necessary to 
elucidate the association between miRNAs and IPF.
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Lung Transplantation: A Final 




Lung transplantation (LTx) is an established, well-recognized medical interven-
tion for treating patients with an end-stage irreversible pulmonary disease. Such 
diseases include interstitial lung disease (ILD), where other standard medical 
options often have been proven as insufficient. Post-operative survival after LTx 
depends on various factors such as the general and organ-specific recipient status in 
addition to donor organ condition and operative technique. The prolonged survival 
rates obtained during the 1980s and 1990s have established LTx in the medical field. 
Reflecting the improvements made in the field of organ preservation, operative 
technique, immunosuppressants, recipient and donor organ selection and prophy-
lactic as well as direct treatment in the wide spectrum of possible infections in the 
recipient. Despite LTx being the golden standard for treating end-stage irreversible 
ILD, with idiopathic pulmonary fibrosis (IPF) as the most common cause, post-
operative outcome is greatly hampered compared to the outcome of other patient 
categories within LTx. This chapter will provide insight in the outcome of ILD and 
subsequently IFP after LTx.
Keywords: lung, transplantation, post-operative outcome, long-term follow-up, 
interstitial lung diseases, interstitial pulmonary fibrosis
1. Introduction
Lung transplantation (LTx) is a known medical intervention for irreversible/
end stage lung diseases, where standard medical treatment has been proven to be 
insufficient, such as patients with end-stage interstitial lung disease (ILD) [1].
Other medical interventions for ILD are restricted to corticosteroids and 
cytotoxic pharmaceuticals with reports showing up to 90% of this patient group as 
non-responsive to pharmaceuticals [2–4].
Idiopathic pulmonary fibrosis (IPF) was the diagnosis for the first LTx among 
long-term surviving patients that was successful, performed in 1983 at Toronto. IPF 
is regularly found in recipients that have undertaken LTx for end-stage pulmonary 
disease [5, 6].
ILD is problematic to treat and often with poor prognosis. Especially IPF that has 
an outcome that is among the poorest in ILD, with a median survival of up to 3 years 
after time of diagnosis [7]. As IPF is an incurable disease, it has additionally been 
reported that if untreated presents with a 5-year survival of 30–50% [3, 4, 8, 9].
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Reflecting the improvements made in the field of organ preservation, operative 
technique, immunosuppressants, recipient and donor organ selection and prophy-
lactic as well as direct treatment in the wide spectrum of possible infections in the 
recipient. Despite LTx being the golden standard for treating end-stage irreversible 
ILD, with idiopathic pulmonary fibrosis (IPF) as the most common cause, post-
operative outcome is greatly hampered compared to the outcome of other patient 
categories within LTx. This chapter will provide insight in the outcome of ILD and 
subsequently IFP after LTx.
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interstitial lung diseases, interstitial pulmonary fibrosis
1. Introduction
Lung transplantation (LTx) is a known medical intervention for irreversible/
end stage lung diseases, where standard medical treatment has been proven to be 
insufficient, such as patients with end-stage interstitial lung disease (ILD) [1].
Other medical interventions for ILD are restricted to corticosteroids and 
cytotoxic pharmaceuticals with reports showing up to 90% of this patient group as 
non-responsive to pharmaceuticals [2–4].
Idiopathic pulmonary fibrosis (IPF) was the diagnosis for the first LTx among 
long-term surviving patients that was successful, performed in 1983 at Toronto. IPF 
is regularly found in recipients that have undertaken LTx for end-stage pulmonary 
disease [5, 6].
ILD is problematic to treat and often with poor prognosis. Especially IPF that has 
an outcome that is among the poorest in ILD, with a median survival of up to 3 years 
after time of diagnosis [7]. As IPF is an incurable disease, it has additionally been 
reported that if untreated presents with a 5-year survival of 30–50% [3, 4, 8, 9].
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Post-operative outcome of LTx rests on several aspects, for instance general 
and organ specific patient status, donor graft status and operative method. The 
extended survival estimates attained in the 80s and 90s most probably mirror 
developments in graft preservation, operative practice, immunosuppressive agents, 
recipient/donor graft selection, and prophylactic therapies of opportunistic infec-
tions in the recipient [10].
These progressions in averting early adverse events have permitted a wider 
incline of indications in LTx with a steady liberalization of donor criteria. This 
has provided a general growth in LTx, although this quantity is yet to date con-
strained by donor organ scarcity. Even though numerous difficulties after LTx 
persist (e.g., opportunistic infections, graft rejection, and pathological relapse in 
the donor graft), LTx is the definitive option for candidates with advanced loss 
of pulmonary function triggered by advanced IPF. The quantity of LTxs achieved 
is principally restricted by the low availability of donor organs [11]. Survival 
is meager for IPF recipients when compared to basically all other pulmonary 
disease groups.
2. Patients and methods
2.1 Transplant procedure
Five types of Tx procedures are normally presented:
• Single lung transplantation (SLTx)
• Double lung transplantation (DLTx)
• Heart-lung transplantation (HLTx)
• Cadaveric lobar transplants (CLTx)
• Transplantation of lobes from living related donors
Throughout the course of listing a patient with ILD for LTx, the patient’s 
indication for Tx as well as preference for DLTx or SLTx, comorbidities, opera-
tive risk, blood type, and donor specific antibodies are investigated beforehand. 
Both SLTx and DLTx are achieved in recipients with IPF and discussion is pres-
ent yet to date whether SLTx or DLTx is the superior alternative in this specific 
group [12].
2.2 Recipient selection
Recipients are selected differently from center to center. In the Lund university 
model as an example, recipients can be selected according to the guidelines by 
the consensus report from the Pulmonary Scientific Council of the International 
Society for Heart and Lung Transplantation [13]. Inclusion norms are often can-
didates diagnosed with chronic lung pathology who are non-responsive to other 
medical treatment. LTx candidates characteristically have a life expectancy of less 
than 18 months and are often dependent on additional oxygen present and are often 
physically restricted. Before entering a LTx programme, candidates usually undergo 
a clinical investigation that can consist of following:
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a. evaluation of kidney function (GFR) by iohexol clearance;
b. immunological screening;
c. microbiological screening;




h. stress test with arterial blood gas, lung scintigraphy and spirometry;
i. Doppler of the carotid arteries (>50 years);
j. CT scan of the chest and abdomen;
k. echocardiogram;
l. coronary angiography of coronary blood vessels; and
m. 24 hours pH evaluation, sometimes followed by gastroscopy.
Patients are often reviewed by a multidisciplinary team before accepted for LTx. 
Recipient/donor matching can be based on ABO blood type and graft size.
The United Network for Organ Sharing (UNOS) has implemented a lung alloca-
tion score (LAS) in the United States. The LAS is a resolve to classify patients in most 
need of a LTx. The LAS is designed by means of numerous evaluations of a patient’s 
status that approximate outcome and predicting the period of survival with or with-
out a LTx. Application of the LAS gave rise to an improved quantity of IPF patients 
getting a LTx as IPF developed into the biggest and most common major indication 
to accept a LTx in 2007 in the United States [14]. In 2011, patients with IPF yielded 
the biggest proportion (46%) of candidates on the LTx wait-list in the US.
Diverse clinical methods are utilized to properly rank for LTx. Biopsy results 
are supportive in deciding the precise diagnosis for IPF [13, 15]. Conventionally, 
numerous clinicians have utilized lung function tests to decide the appropriate 
period of listing a ILD/IPF patient for LTx, with a report that lung function testing 
through diffusion pulmonary function for CO < 39% may predict early mortality 
[16] in addition to 6-minute walk test (6MWT) that can predict early mortality [17]. 
Radiologic findings are of great value in sorting ILD patients in terms of hazard. 
High-resolution computed tomography has shown that a greater grade of fibrosis 
forecasts greater risk for death [18, 19].
Patients with IPF although placed on the waiting list for LTx, such a patient is 
still exposed to great hazard. In history, IPF patients have the highest waiting list 
mortality estimates of all candidates for LTx [20, 21]. Before the LAS, candidates 
with IPF showed a waiting list mortality between 28 and 47% with other recipient 
groups presenting a waiting-list mortality at only 15% [2, 3, 22]. Due to the great 
risk in mortality as well as morbidity on the waiting list, it is of great interest to 
investigate methods to optimize this process. 15-step oximetry test, 6MWT as well as 
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the quantity of oxygen that the IPF recipient is dependent on have all a role to play in 
reflecting the risk of mortality on the waiting list [22–24]. Further improvements are 
needed in maintaining the well-being of this patient group in waiting for a LTx.
2.3 Donor organ selection
Matching a donor lung with a recipient can be grounded on donor/recipient 
height and even pulmonary volume from chest radiographs [25, 26]. The optimal 
grade of fit is not known and the association between donor and recipient do not 
have to be a perfect match, but a close match is favored in terms of size [27].
“Ideal donor criteria” are often thought of as age < 55 years, normal chest X-ray, 
PaO2/FiO2 > 300 mmHg at five PEEP, <20 pack year smoking history, lack of chest 
trauma and lack of aspiration/sepsis [27, 28].
2.4 Immunosuppression
Maintenance of immunoregulation depends on the center and region. With the 
Lund University model as an example, it has remained more or less the same during 
the LTx programmes inception, based on a practice of cyclosporine, corticosteroids 
and azathioprine or mykofenolatmofetil as a lifelong routine.
2.5 Antimicrobial and infection prophylaxis
LTx patients are at increased hazard for infectious difficulties because of subse-
quent features:
• High level of immunosuppression to prevent rejection
• Adversative consequences from Tx on the lung host defenses
• Persistent environmental interaction permitting microbiological agents direct 
admission into the graft
The probability and category of infection differs with the degree of recipi-
ent immunosuppression, timing since LTx, variety and period of anti-microbial 
prophylaxis in addition to the local center and regional microbiology. The most 
common type presented in LTx recipients are bacterial pneumonia [29, 30].
Prophylactic administration of broad-spectrum antibiotics such as carbapenem 
are preferred until cultures can be available and then initiate target treatment for 
specific infection. Antiviral therapy may be directed against CMV for recipients 
with positive CMV serology. Preoperative screening for CMV is performed rou-
tinely in recipients/donors. Antifungal prophylaxis may include low-dose  
fluconazole for Candida and sulfametoxazol/trimethoprim for Pneumocystis carinii.  
Broad-spectrum antibiotics with colistin may be utilized for Pseudomonas if 
present.
2.6 Follow-up
Routine follow-up after LTx is intended to avert complications or to distinguish 
them as soon as possible. While follow-up is most rigorous during the first year after 
LTx, it is necessary to proceed with a lifetime of follow-up of the LTx recipient. 
Pulmonary function progressively advances and typically scopes a plateau by the 
end of year 1 after LTx [31, 32].
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The practices include:
• Follow-up with a (trained) nurse coordinator




• Selected hematological testing to supervise the immunosuppressive serum 
levels
There are also possibilities for the LTx recipient to be undergo follow-up from 
the home, such as daily home spirometry. This form of monitoring has been associ-
ated with earlier detection of chronic forms of rejection [33–37].
3. Outcomes after LTx
3.1 Survival
Outcome after LTx can be evaluated founded on numerous different measures: 
survival, quality of life, physiologic changes and cost benefit [38, 39]. Survival 
is feasibly the most objective calculation of outcome. The International Society 
for Heart and Lung Transplantation (ISHLT) has created a registry of survival 
estimates from international data that have become a benchmark for the field 
[40, 41]. According to the 2017 ISHLT registry report, the median survival for all 
adult LTx recipients is 6 years [38]. Nevertheless, it is uncertain if survival benefit 
is primarily connected to the type of procedure or the underlying LTx patient’s 
features that does the impact. A report that assessed the influence of patient age 
and procedure on the survival outcome of patients with IPF showed that SLTx 
recipients younger than 60 years displayed a survival benefit over DLTx in the 
same age category [6].
The influence of the diagnostic type of recipient on survival after LTx has 
been studied expansively [38, 42, 43]. The primary major indication is habitu-
ally connected to age. Furthermore, specific diagnostic groups have a greater 
hazard of complications during LTx and primary graft dysfunction (PGD). 
Nevertheless, patients with COPD have the most superior first-year survival but 
then again a worse 10-year survival compared to other recipient groups such 
as pulmonary hypertension, sarcoidosis, and alpha-1 antitrypsin deficiency 
patients [38]. Those with IPF have the lowest 10-year outcome when compared to 
all other diagnostic groups.
Multiple report that have studied the post-LTx survival for IPF patients 
showed that 1-year survival range from 68 to 80%, 3-year survival from 50 to 
61% and 5-year survival between 32 and 59%, with earlier LTx periods even tend 
to have worse outcome than recent LTxs performed [44–48]. There are various 
reports in post-LTx survival from monocentric data from Europe, North America 
as well as Brazil and Australia that show corresponding survival data for 1-year 
survival data ranging between 25 and 87% while 5-year survival has showed 
between 33 and 63% [22, 49–58].
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3.2 DLTx versus SLTx
SLTx was the typical Tx type for recipients with IPF for several years and survival 
outcomes were analogous to other diagnostic groups within LTx [2, 5, 6, 22]. Though, 
a major proportion of IPF recipients are presently undergoing DLTx [59–61].
In 2011, almost half of all IPF patients where DLTxs while the other half where 
almost entirely SLTxs [62]. More than 60% of LTxs in 2014 for IPF recipients was 
DLTx while in 1991 this number was only 15% [60]. This alteration in trend is not 
entirely clear but it has been proposed that probable factors are better operative 
technique in addition to improved pulmonary function and survival for DLTx.
IPF patients that underwent DLTx has shown significantly better survival 
for DLTx versus SLTx, where survival has improved for DLTx patients with IPF 
compared to SLTx patients in this patient category [63]. Especially if IPF patients 
manage to survive beyond the 10-year mark, with attributed survival benefits in 
DLTx [64]. However it has also been reported that IPF patients that underwent 
DLTx do have an increased mortality risk in the early postoperative period [47]. In 
addition, when adjusting for risk factors in such analyses for DLTx vs. SLTx among 
IPF patients, no difference in outcome has been shown [65]. Other single centers 
such as from the US and Australia and data from the ISHLT from the period of 1994 
to 2004 showed no difference in outcome regarding DLTx vs. SLTx for IPF patients 
[53, 66–68]. Interestingly, European centers has been able to show in contrast from 
the literature that SLTx has the ability to yield survival benefit for IPF patients than 
DLTx [69].
Living donor lobar LTx has been proposed as an option for LTx candidates with 
end-stage IPF with low probability to survive the entire period on the waiting list 
for standard donor LTx [70].
3.3 Ventilator support, intensive care and postoperative stay
Few studies have reported data on the early period in hospital stay post-LTx. One 
single center in Sweden however has reported ventilator support, intensive care unit 
stay and overall post-operative stay until discharge for all types of LTx recipients 
including IPF recipients [71]. This report showed that the median time for ventila-
tor support after LTx was 2 days while for IPF patients that required almost 3 days. 
The same pattern followed for intensive care unit time after LTx, showing a median 
of over 6 days for all recipients while PF patients had a median of 8 days. Finally, the 
total time of hospital stay after LTx was a median of 43 days in all recipients while 
IPF patients had one of the longest at 46 days.
The studies that report post-LTx in hospital time and need of medical resources 
suggest that LTx in IPF patients has been associated with substantial resource use.
3.4 Cause of death and complications
Among IPF patients who underwent a LTx in the United States (1987–2009), 
the principal cause of death was infection or sepsis causing almost a quarter of the 
deaths of IPF recipients [2, 22, 47, 50, 55, 65, 68, 72, 73], followed by bronchiolitis 
obliterans syndrome (BOS)/chronic rejection [74].
As infection is the number one cause regarding complications, others causes 
include hemodynamic instability, kidney failure, myopathy, bleeding, and reopera-
tion [75]. Almost a tenth of all LTx recipients may experience airway complications 
[76]. Malignancy is a long-term complication that almost a third of IPF patients 
may experience at 10 years after LTx [77]. In addition it is more common with lung 
embolisms in IPF patients with over a quarter of all patients in this category [49].
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3.5 Rejection
PGD, a form of acute rejection is a severe complication that is a risk for all LTx 
recipients which include ILD patients. The background for this pathology depends 
on several factors though ischemia-reperfusion injury is assumed to be the main 
instrument of this pathology [78]. The incidence has been reported to be between 
10 and 25% [78, 79]. Nonetheless, PGD in ILD patients are significantly more 
associated with worse mortality in the early outcome, whilst in the long-term is 
has been associated with increased risk of a form of chronic rejection as BOS [80]. 
Despite pulmonary hypertension recipients having a higher incidence of ischemia-
reperfusion injury, recipients with IPF have a higher probability of experiencing 
ischemia-reperfusion injury than COPD patients, putting them at greater hazard of 
experiencing PGD [81].
BOS, a form of chronic lung allograft dysfunction, is the biggest factor hamper-
ing long-term outcome. Regrettably, it is likewise a common obstacle in LTx, where 
LTx recipients in general experience an incidence of almost 30% after 2 years and 
three quarters of recipients experience this pathology after 10 years [77, 82].  
Recipients with IPF have a greater hazard of contracting PGD and therefore a 
greater hazard of BOS, where it is proposed that this patient group have steeper 
deterioration in lung function and greater risk of mortality than recipients without 
IPF that has been exposed to BOS [83, 84].
4. Conclusions
LTx is a well-known treatment strategy for an extensive number of irreversible 
end-stage pulmonary disease, including ILD with focus on IPF. There is yet to date 
a great gap among patients that is qualified and patients that are admitted for a LTx. 
IPF patients have a greater mortality on the waiting list versus other major indica-
tions. A great share of IPF patients decease before the possibility of undergoing LTx. 
This makes it important to prioritize this patient population for LTx as the need is 
unfortunately not met. IPF patients have been linked to greater risk of complications 
than other patient groups in parameters such as time in the intensive care unit, time 
in mechanical ventilator and in hospital time. It is still not entirely clear whether a 
SLTx or a DLTx is of greatest benefit to a IPF patient. The most recent trend has been 
in favor for DLTx rather than SLTx. It has been suggested that the increased survival 
in IPF patients is due to DLTx while on the other hand the data is conflicting. It is pos-
sible that a more accurate survival benefit is resulted among different subcategories 
of IPF candidates whilst on the other hand certain IPF candidates may not yield any 
survival benefit at all from a DLTx where greater understanding is required.
The application of the LAS has reduced the time on the waiting list and 
improved survival by yielding precedence for patients that are in the greatest need 
for a LTx. The implementation of the LAS gave rise to the IPF patient category to 
even surpass COPD as the greatest indication to undergo LTx. However, carrying 
out LTx in candidates with a greater LAS score does result in more extensive use of 
medical resources.
There is no curative treatment for IPF patients with a miserable prognosis. 
Up-to-date strategies for the inclusion of LTx candidates endorse that suitable IPF 
patients ought to be recruited for LTx at the earliest. IPF recipients show the worst 
outcome of all LTx patients in addition to the donor pool being hampered by the 
scarcity of donor organs. It is therefore essential that qualified ILD patients and 
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total time of hospital stay after LTx was a median of 43 days in all recipients while 
IPF patients had one of the longest at 46 days.
The studies that report post-LTx in hospital time and need of medical resources 
suggest that LTx in IPF patients has been associated with substantial resource use.
3.4 Cause of death and complications
Among IPF patients who underwent a LTx in the United States (1987–2009), 
the principal cause of death was infection or sepsis causing almost a quarter of the 
deaths of IPF recipients [2, 22, 47, 50, 55, 65, 68, 72, 73], followed by bronchiolitis 
obliterans syndrome (BOS)/chronic rejection [74].
As infection is the number one cause regarding complications, others causes 
include hemodynamic instability, kidney failure, myopathy, bleeding, and reopera-
tion [75]. Almost a tenth of all LTx recipients may experience airway complications 
[76]. Malignancy is a long-term complication that almost a third of IPF patients 
may experience at 10 years after LTx [77]. In addition it is more common with lung 
embolisms in IPF patients with over a quarter of all patients in this category [49].
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3.5 Rejection
PGD, a form of acute rejection is a severe complication that is a risk for all LTx 
recipients which include ILD patients. The background for this pathology depends 
on several factors though ischemia-reperfusion injury is assumed to be the main 
instrument of this pathology [78]. The incidence has been reported to be between 
10 and 25% [78, 79]. Nonetheless, PGD in ILD patients are significantly more 
associated with worse mortality in the early outcome, whilst in the long-term is 
has been associated with increased risk of a form of chronic rejection as BOS [80]. 
Despite pulmonary hypertension recipients having a higher incidence of ischemia-
reperfusion injury, recipients with IPF have a higher probability of experiencing 
ischemia-reperfusion injury than COPD patients, putting them at greater hazard of 
experiencing PGD [81].
BOS, a form of chronic lung allograft dysfunction, is the biggest factor hamper-
ing long-term outcome. Regrettably, it is likewise a common obstacle in LTx, where 
LTx recipients in general experience an incidence of almost 30% after 2 years and 
three quarters of recipients experience this pathology after 10 years [77, 82].  
Recipients with IPF have a greater hazard of contracting PGD and therefore a 
greater hazard of BOS, where it is proposed that this patient group have steeper 
deterioration in lung function and greater risk of mortality than recipients without 
IPF that has been exposed to BOS [83, 84].
4. Conclusions
LTx is a well-known treatment strategy for an extensive number of irreversible 
end-stage pulmonary disease, including ILD with focus on IPF. There is yet to date 
a great gap among patients that is qualified and patients that are admitted for a LTx. 
IPF patients have a greater mortality on the waiting list versus other major indica-
tions. A great share of IPF patients decease before the possibility of undergoing LTx. 
This makes it important to prioritize this patient population for LTx as the need is 
unfortunately not met. IPF patients have been linked to greater risk of complications 
than other patient groups in parameters such as time in the intensive care unit, time 
in mechanical ventilator and in hospital time. It is still not entirely clear whether a 
SLTx or a DLTx is of greatest benefit to a IPF patient. The most recent trend has been 
in favor for DLTx rather than SLTx. It has been suggested that the increased survival 
in IPF patients is due to DLTx while on the other hand the data is conflicting. It is pos-
sible that a more accurate survival benefit is resulted among different subcategories 
of IPF candidates whilst on the other hand certain IPF candidates may not yield any 
survival benefit at all from a DLTx where greater understanding is required.
The application of the LAS has reduced the time on the waiting list and 
improved survival by yielding precedence for patients that are in the greatest need 
for a LTx. The implementation of the LAS gave rise to the IPF patient category to 
even surpass COPD as the greatest indication to undergo LTx. However, carrying 
out LTx in candidates with a greater LAS score does result in more extensive use of 
medical resources.
There is no curative treatment for IPF patients with a miserable prognosis. 
Up-to-date strategies for the inclusion of LTx candidates endorse that suitable IPF 
patients ought to be recruited for LTx at the earliest. IPF recipients show the worst 
outcome of all LTx patients in addition to the donor pool being hampered by the 
scarcity of donor organs. It is therefore essential that qualified ILD patients and 
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Lung Transplant for Interstitial 
Lung Diseases
Brandon Nokes, Eugene Golts and Kamyar Afshar
Abstract
Lung transplant is an important treatment modality for select cases of advanced 
interstitial lung disease. However, the pre- and postoperative management requires sev-
eral unique considerations. The decision to transplant is based largely on clinical sever-
ity of illness and the lung allocation score. Transplant improves overall mortality across 
the interstitial lung diseases, though not all ILD subtypes experience equal benefit from 
lung transplant. Broadly speaking, there is no difference in benefit between single- and 
bilateral-lung transplants, though we will discuss some important clinical nuances to 
this decision as well. Lastly, there are a number of immunosuppression, coagulation, 
and malignancy risk considerations that must be carefully understood in caring for the 
lung transplant patient. This chapter will provide a general overview of the indications 
for lung transplant, risk stratification for lung transplant across the interstitial lung 
diseases, as well as general postoperative management details.
Keywords: interstitial lung diseases, usual interstitial pneumonia, lung transplant, 
lung allocation score, immunosuppression
1. Introduction
Lung transplantation is a therapeutic surgical option for selected patients with 
severe pulmonary disease who are refractory to medical therapy and continue to 
have progressive clinical deterioration [1]. As is discussed elsewhere in this book, 
the idiopathic interstitial pneumonias (IIPs) that require lung transplantation 
include idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), 
nonspecific interstitial pneumonia (NSIP), and acute interstitial pneumonia (AIP). 
The non-IIP ILD groups that are routinely evaluated for lung transplant include 
sarcoidosis, hypersensitivity pneumonitis (HP), rheumatologically associated UIP 
and NSIP, as well as lymphangioleiomyomatosis (LAM).
The general guidelines for lung transplantation consideration include (1) high 
(>50%) risk of death from lung disease within 2 years without transplant, (2) high 
(>80%) likelihood of surviving at least 90 days after lung transplantation, and (3) 
high (>80%) likelihood of 5-year posttransplant survival from a general medical 
perspective provided that there is adequate graft function [1]. Within the United 
States, between 1995 and 2015, ILDs accounted for 29.7% (n = 14,828) of lung 
transplants [1]. Collectively, the ILDs were the second most common indication for 
transplant behind chronic obstructive pulmonary disease without alpha-1-antitryp-
sin deficiency [1]. Of those patients, 6956 received single-lung transplant, and 7872 
received bilateral-lung transplants [1]. Importantly, the ILD diagnostic subclasses 
were subdivided into idiopathic interstitial pneumonias (IIP) (n = 12,243) as well 
39
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Abstract
Lung transplant is an important treatment modality for select cases of advanced 
interstitial lung disease. However, the pre- and postoperative management requires sev-
eral unique considerations. The decision to transplant is based largely on clinical sever-
ity of illness and the lung allocation score. Transplant improves overall mortality across 
the interstitial lung diseases, though not all ILD subtypes experience equal benefit from 
lung transplant. Broadly speaking, there is no difference in benefit between single- and 
bilateral-lung transplants, though we will discuss some important clinical nuances to 
this decision as well. Lastly, there are a number of immunosuppression, coagulation, 
and malignancy risk considerations that must be carefully understood in caring for the 
lung transplant patient. This chapter will provide a general overview of the indications 
for lung transplant, risk stratification for lung transplant across the interstitial lung 
diseases, as well as general postoperative management details.
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1. Introduction
Lung transplantation is a therapeutic surgical option for selected patients with 
severe pulmonary disease who are refractory to medical therapy and continue to 
have progressive clinical deterioration [1]. As is discussed elsewhere in this book, 
the idiopathic interstitial pneumonias (IIPs) that require lung transplantation 
include idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), 
nonspecific interstitial pneumonia (NSIP), and acute interstitial pneumonia (AIP). 
The non-IIP ILD groups that are routinely evaluated for lung transplant include 
sarcoidosis, hypersensitivity pneumonitis (HP), rheumatologically associated UIP 
and NSIP, as well as lymphangioleiomyomatosis (LAM).
The general guidelines for lung transplantation consideration include (1) high 
(>50%) risk of death from lung disease within 2 years without transplant, (2) high 
(>80%) likelihood of surviving at least 90 days after lung transplantation, and (3) 
high (>80%) likelihood of 5-year posttransplant survival from a general medical 
perspective provided that there is adequate graft function [1]. Within the United 
States, between 1995 and 2015, ILDs accounted for 29.7% (n = 14,828) of lung 
transplants [1]. Collectively, the ILDs were the second most common indication for 
transplant behind chronic obstructive pulmonary disease without alpha-1-antitryp-
sin deficiency [1]. Of those patients, 6956 received single-lung transplant, and 7872 
received bilateral-lung transplants [1]. Importantly, the ILD diagnostic subclasses 
were subdivided into idiopathic interstitial pneumonias (IIP) (n = 12,243) as well 
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as ILD, not-IIP (n = 2585) (Table 1). Sarcoidosis, obliterative bronchiolitis (OB), 
and connective tissue disorder (CTD) were also listed diagnostic indications, and 
so there exists the potential for overlapping and misclassification of the underlying 
disease leading to lung transplant in a small proportion of cases. Irrespective of the 
subtype, ILDs present a unique challenge from pretransplant selection to postopera-
tive care. The pre- and posttransplant clinical courses for each of these pathologies 
will be detailed within this chapter.
2. The lung allocation score (LAS) and the decision to transplant
An important part of the preoperative evaluation is individual assessment of 
patient risk with and without transplant. Some European countries, like France and 
Switzerland, have a national urgency list. Others, including the United Kingdom, 
allocate donor lungs according to individual transplant center decisions. More than 
60% of the worldwide lung transplant activity, however, is allocated by the lung 
allocation score (LAS) [2]. The LAS has been adopted in many countries as a means 
of minimizing waitlist mortality [2]. The LAS is a calculated score (from 0 to 100) 
used to predict waitlist survival probability with and without a lung transplant for 
patients over the age of 12. Higher LAS scores impart a higher likelihood of waitlist 
mortality and allow for a prognostic stratification within regional transplant wait-
lists and associated organ allocation preference [2]. This multifactorial system com-
bines pulmonary function data with clinical comorbidity data. The implementation 
of this system has resulted in a substantial reduction in waitlist mortality and for the 
more expeditious mobilization of organs on a needs-based assessment [3]. Moreover, 
the median waitlist time in the United States has dropped from 4.1 to 2.1 months 
since the adoption of the LAS [2]. As such, the LAS has since been adopted in a num-
ber of other countries’ transplant programs [4, 5]. Similar OLT outcomes research 
has been conducted on healthcare-related quality of life (HRQL) after transplant, 
and in general, higher LAS imparts a greater improvement in HRQL after OLT [6]. 
This benefit appears to diminish with greater age, especially after age 65 [6].
Despite the shorter waitlist time with higher LAS score, some patients may 
remain on the waitlist for longer periods of time. This is a reflection of a number of 
logistic limitations underpinning the lung transplant process. Notably, the number 
of available lung allografts does not meet the current US or global need. Up to 
Table 1. 
Common drug-drug interactions with immunosuppressants—adapted from [37].
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20% of lung transplant candidates are inactivated or die before an adequate donor 
becomes available [7]. Moreover, explanted lungs are inherently fragile, which fur-
ther complicates the transplant process. Recipient underlying lung disease greatly 
matters in the type of transplant procedure required, e.g., unilateral vs. bilateral 
OLT. Donor and recipient lung size match is essential for adequate function of the 
allograft as well as survival [8]. Shorter patients may require lung donors from 
pediatric patients. However, pediatric lungs are first offered to pediatric candidates 
(age < 18 years) before they become available to other potential recipients.
Donors and recipient ABO blood type and human leukocyte antigen (HLA) 
compatibility must also be considered. Ideally, patients will have absent panel-
reactive antibodies (PRA). Notably, only 69.8% of lung transplant candidates had 
0% PRA since 2009. Patients with a higher PRA, particularly PRA greater than 
25%, have a higher 30-day and overall mortality [9]. This makes the waitlist time 
for an appropriate crossmatch significantly longer and can potentially exclude the 
candidate from transplantation due to elevated risk of rejection.
The underlying diagnosis necessitating transplant also impacts the LAS. With 
respect to ILD, individuals with IPF and sarcoidosis are more likely to have a higher 
LAS than more common diagnoses such as COPD [3]. With LAS scores greater than 
60, individuals with IPF have a greater risk of posttransplant mortality. Although 
no strict stratification exists to say at which LAS transplant should be avoided, this 
decision is left to local transplant centers when the risk is exceedingly high [3].
3. Idiopathic pulmonary fibrosis (IPF) lung transplant overview
Given the relative preponderance of IPF as a pretransplant diagnosis in com-
parison to the other ILDs, a brief overview of IPF outcomes following transplant 
is included here. The most common of the ILDs to necessitate transplant is IPF, 
which accounts for roughly 46% of patients on the lung transplant waiting list 
according to 2011 data from the Organ Procurement and Transplantation Network 
(OPTN) [10]. Importantly, IPF has no definitive treatment and an average survival 
of 2–3 years after diagnosis. It is associated with older age, male sex, and smoking 
history. It has also been associated with shortened telomere length, both in familial 
and sporadic forms [11]. This finding has been demonstrated in both peripheral 
blood leukocytes and postmortem lung tissue samples [11]. There are no targeted 
therapies readily available to curtail this epigenetic proclivity, but as IPF progresses, 
OLT remains a life-saving measure, with a median survival of 4.5 years after 
transplant for both bilateral- (BLT) and single-lung transplant (SLT) [12]. A recent 
meta-analysis suggested that those with BLT may have improved survival when 
compared to SLT, but this may be a result of selection bias [12]. Importantly, only 
those with end-stage bronchiectasis and idiopathic pulmonary arterial hypertension 
(IPAH) require BLT, and essentially all other diagnoses are suitable for SLT [12].
The clinical time course for IPF is heterogeneous, but there is invariably a clinical 
and functional decline, and many of these patients will have to go for transplant 
(Figure 1) [13]. The survival after transplant is the poorest for IPF relative to other 
indications for OLT, with the exception of re-transplant (Figure 2) [1]. As noted, the 
implementation of the LAS has allowed more rapid allocation of allografts for IPF 
and has improved prognosis tremendously. Further, although the median FVC for 
IPF at time of transplant is ~40–45%, this improves to 65% after transplant, contin-
gent on selecting appropriate donor size [14]. Predicted total lung capacity (pTLC) 
can be used to approximate appropriate donor lung size for SLT or BLT [14]. In the 
absence of postoperative graft dysfunction, improvements can also be expected in 
HRQL, 6-minute walk test (6MWT), PaO2, and dyspnea severity [15, 16].
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is included here. The most common of the ILDs to necessitate transplant is IPF, 
which accounts for roughly 46% of patients on the lung transplant waiting list 
according to 2011 data from the Organ Procurement and Transplantation Network 
(OPTN) [10]. Importantly, IPF has no definitive treatment and an average survival 
of 2–3 years after diagnosis. It is associated with older age, male sex, and smoking 
history. It has also been associated with shortened telomere length, both in familial 
and sporadic forms [11]. This finding has been demonstrated in both peripheral 
blood leukocytes and postmortem lung tissue samples [11]. There are no targeted 
therapies readily available to curtail this epigenetic proclivity, but as IPF progresses, 
OLT remains a life-saving measure, with a median survival of 4.5 years after 
transplant for both bilateral- (BLT) and single-lung transplant (SLT) [12]. A recent 
meta-analysis suggested that those with BLT may have improved survival when 
compared to SLT, but this may be a result of selection bias [12]. Importantly, only 
those with end-stage bronchiectasis and idiopathic pulmonary arterial hypertension 
(IPAH) require BLT, and essentially all other diagnoses are suitable for SLT [12].
The clinical time course for IPF is heterogeneous, but there is invariably a clinical 
and functional decline, and many of these patients will have to go for transplant 
(Figure 1) [13]. The survival after transplant is the poorest for IPF relative to other 
indications for OLT, with the exception of re-transplant (Figure 2) [1]. As noted, the 
implementation of the LAS has allowed more rapid allocation of allografts for IPF 
and has improved prognosis tremendously. Further, although the median FVC for 
IPF at time of transplant is ~40–45%, this improves to 65% after transplant, contin-
gent on selecting appropriate donor size [14]. Predicted total lung capacity (pTLC) 
can be used to approximate appropriate donor lung size for SLT or BLT [14]. In the 
absence of postoperative graft dysfunction, improvements can also be expected in 
HRQL, 6-minute walk test (6MWT), PaO2, and dyspnea severity [15, 16].
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4. Issues addressed while awaiting lung transplantation
4.1 Short telomere length
Rare mutations in the telomere pathways (NAD1, PARN, RTELI, TERC, TERT) 
are found in familial pulmonary fibrosis [11, 17]. Having short telomere length is 
characterized by earlier onset of IPF, associated liver disease, impaired CMV immu-
nity, and bone marrow suppression [11, 17, 18]. Newton et al. conducted an observa-
tion cohort study of IPF patients who underwent lung transplantation [19]. Patients 
were stratified into two groups based on the telomere length; 32 patients were in 
Group 1 (telomere length < 10th percentile). They were compared to the 56 patients 
in Group 2 (telomere length ≥ 10th percentile). There were no difference between 
the two groups with regard to baseline demographics and severity of lung disease. 
Figure 1. 
Clinical course of patients with idiopathic pulmonary fibrosis. Many follow the course of the slow progressive 
decline. A minority will have a rapidly progressive course. An acute exacerbation can occur at any point in the 
course of functional decline. Rapidly progressive; acute exacerbations; and slowly progressive. Adapted from [51].
Figure 2. 
Kaplan-Meier survival by diagnosis for adult lung transplants performed between January 1990 and June 2010. 
Alpha-1, α1-antitrypsin deficiency emphysema; CF, cystic fibrosis; COPD, chronic obstructive pulmonary 
disease; IPF, idiopathic pulmonary fibrosis; PAH, pulmonary arterial hypertension—adapted from [38].
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Group 1 lung transplant recipients had higher incidence of primary graft dysfunction 
grade 3 and earlier time to chronic allograft dysfunction. There was no difference in 
the incidence of acute allograft rejection, cytopenias, or infections. Popescu et al. 
reported the increased risk of Cytomegalovirus (CMV) infections in the short telomere 
IPF lung transplant recipients [18]. Given this knowledge, some lung transplant cen-
ters will only accept CMV-negative donor lungs in order to reduce risk of transmission 
and CMV-related complications. In the case series of eight patients by Silhan et al., 
these lung transplant recipients with short telomere tolerated a dual drug immu-
nosuppression [20]. The antimetabolites could be easily withdrawn. Hematological 
complications occurred in four lung transplant recipients, with two cases of known 
bone marrow failure prior to lung transplantation. There was a 12% platelet transfu-
sion rate. Several patients had infectious complications with gram-negative pneu-
monia/sepsis, fungal infections, and CMV disease (pneumonitis). These patients 
developed acute kidney injury, with half of them requiring renal replacement therapy.
5. Studies on OFEV/Esbriet prior to lung transplantation
Many centers were initially reluctant to the use of nintedanib in IPF patient 
listed for lung transplant due to its potential to increase perioperative bleeding risk 
and impaired wound healing, thereby causing bronchial anastomotic complica-
tions. These concerns have been alleviated with recent publications that indicate 
no worsening of airway complications or bleeding risks [21, 22]. Four of the nine 
patients in Balestro et al.’s study required intraoperative venoarterial or veno-veno 
extracorporeal membrane oxygenation (ECMO) [21]. No patient experienced major 
bleeding, despite being on nintedanib as well as aspirin + clopidogrel. There were 
also no reports of airway anastomotic dehiscence.
The exact mechanism of action of pirfenidone may be from the inhibition of 
transforming growth factor beta (TGF-b) [23]. A few case reports describe the 
safety of pirfenidone use as a bridge to lung transplantation [24, 25].
Mortensen et al. reported the largest retrospective analysis of 18 IPF patients 
who took pirfenidone prior to lung transplantation [25]. Only one patient devel-
oped sternal dehiscence that was more related to a surgical issue. There was no 
airway dehiscence in any of the 18 patients.
6. Other preoperative immunosuppressive considerations
Many patients with sarcoidosis, hypersensitivity pneumonitis, and rheumato-
logically induced ILD require corticosteroids to help control respiratory symptoms 
and further lung parenchymal inflammation. Chronic steroid use can lead to 
thinning of the skin, myopathy, and delayed wound healing [26]. McAnally et al. 
reported the deleterious effects of pretransplant corticosteroids [27]. Sixty six 
percent of their patients awaiting lung transplantation were on corticosteroids. The 
132 patients in the low-dose steroid group (<0.42 mg/kg/m2) were compared to the 
69 high-dose steroid group (≥0.42 mg/kg/m2). Patients were clinically similar based 
on underlying lung disease, severity of lung function, transplant type, and donor 
lung ischemic time. The high-dose steroid group had higher rates of serious infec-
tions and delayed wound healing as well as higher risk of early posttransplant death. 
The general recommendations are not only to minimize the steroid dose to allow for 
continued stabilization of underlying ILD but also to minimize complications with 
bridge to lung transplantation.
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Lymphangioleiomyomatosis is characterized by proliferation of LAM cells, 
the abnormal smooth muscle-like cells that metastasize to lead cystic changes 
seen on chest radiograph. The cysts are present throughout both lung fields, 
although they predominate in the lower lung region. Their size can vary from 
3 mm up to 3 cm. Larger cysts (>0.5 cm) are more likely to cause pneumothoraces 
[28]. Pneumothoraces occur in up to 60–70% of women with LAM. A majority 
of first-time pneumothoraces occur in the third and fourth decade of life [29]. 
Unfortunately, they are not a one-time event for most LAM patients. Four percent 
of these individuals can have simultaneous bilateral pneumothoraces. Recurrence 
rates for pneumothoraces are upward of 70%. Sirolimus, an mTOR inhibitor, is 
currently recommended as therapy for LAM. It blocks the signaling pathway for 
the growth and proliferation of the LAM cells that cause all the clinical manifesta-
tions described. Common adverse events when taking sirolimus include mucositis, 
diarrhea, nausea, hypercholesterolemia, and lower extremity edema. The most 
relevant adverse events of sirolimus in the context of this chapter are poor wound 
healing and anastomotic dehiscence in perioperative periods [30–32]. Dilling et al. 
reported their experience of continued use of sirolimus in patients with LAM 
while awaiting lung transplantation [33]. All patients were continued on their 
maintenance sirolimus dose up to the day of lung transplantation. None of the 
patients developed increased bleeding or wound dehiscence. In select patients, the 
use of sirolimus may be required. Lymphangioleiomyomatosis can recur follow-
ing lung transplantation. It may present itself primarily as a chylous effusion. If a 
single-lung transplant is performed, the cystic lung disease can continue to prog-
ress. Sirolimus can be added to the maintenance immunosuppression to help the 
underlying process. There is varying reports on the safety of sirolimus use in early 
post-lung transplantation [31, 34].
7. Medical care of the lung transplant patient
The medical care after OLT requires close coordination between a multidisci-
plinary transplant team, including but not limited to transplant pulmonologists, 
cardiothoracic surgeons, pharmacists, physical/occupational/respiratory therapists, 
social workers, transplant nurses, and patient advocates. The transplant committee 
decision-making process for transplant eligibility is complex and beyond the scope 
of this text. However, important consideration elements of note are functional 
status, including physical ability to tolerate and recover from OLT [1]. To this end, 
physical therapy and nutritional optimization are paramount in the pretransplant 
process in order to ensure posttransplant success. Many inpatients that are listed for 
transplant have achieved benefit from early veno-venous extracorporeal membra-
nous oxygenation (VV-ECMO) in order to facilitate mobilization and engagement 
with physical therapy [35, 36].
Transplant infectious disease specialists can be helpful in directing region-
ally appropriate infectious disease screening/treatment prior to transplant. 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) status assessments 
between donor and recipient are paramount in guiding postoperative antiviral 
therapy, with CMV +/− and CMV −/+ being prophylaxed with valganciclovir and 
CMV −/− receiving acyclovir. EBV status is helpful in determining immunosup-
pressive needs. Over-immunosuppression can increase the risk of posttransplant 
lymphoproliferative disorder (PTLD), a lymphoma-like condition that responds to 
reduction in immunosuppression. All lung transplant recipients receive high-dose 
glucocorticoid treatment and require pneumocystis prophylaxis, typically with 
trimethoprim-sulfamethoxazole.
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7.1 Complications following lung transplant
Acute rejection rates are extremely common in the first year after lung 
transplantation with approximately 30–40% of recipients having at least one 
episode in the first year after transplant. Triple-drug immunosuppressive agents 
have become the standard of care and are prescribed to minimize this risk [37]. 
Immunosuppressive dosing must be carefully considered so as to minimize acute 
rejection risk without leading way to infections. The regimen typically prescribed 
in lung and most solid organ transplants typically includes prednisone, a calcineu-
rin inhibitor (tacrolimus or cyclosporine), and an antimetabolite (azathioprine 
or mycophenolate mofetil). Despite the unique side effects of each of these drug 
classes, the cumulative effect of immunosuppression may predispose individuals to 
opportunistic infections, renal failure, malignancies, posttransplant hypertension, 
diabetes, and dyslipidemia. Table 1 reviews common drug interactions that can 
alter immunosuppressant clearance or therapeutic drug levels.
The lung allograft is subject to a variety of insults resulting in various paren-
chymal abnormalities. These complications are broadly classified as infectious and 
noninfectious. The development of infections is the leading cause of morbidity and 
mortality in the first 3 years following lung transplantation [38]. Bacterial patho-
gens are the most common, but fungal and viral infections are also particularly 
important (especially Aspergillus and Cytomegalovirus).
Despite their ubiquitous and potentially ominous nature, radiographic pulmo-
nary parenchymal abnormalities predicting posttransplant complication can be 
nonspecific (Figures 3–5). Bacterial and fungal radiographic features are highly 
varied and include consolidation, ill-defined nodules, cavitation, and ground-glass 
opacifications, making them difficult to identify. Viral infections (especially CMV) 
may have normal radiographs. They can also show ground-glass, micronodules, 
consolidation, and/or reticulonodular opacities.
Moreover, acute cellular rejection (ACR) can present similar to any of the previ-
ously mentioned complications. ACR radiographic features can appear as normal 
radiograph, ground-glass opacities, alveolar opacities, consolidation, nodules, as 
well as a new or evolving pleural effusion (seen in 43% of patients) [39, 40].
Due to the radiographic overlap in postoperative lung pathologies, broad-
spectrum antimicrobial therapy is often instituted in the acutely ill lung transplant 
Figure 3. 
Chest X-ray of a single-lung transplant recipient for IPF.
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CMV −/− receiving acyclovir. EBV status is helpful in determining immunosup-
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7.1 Complications following lung transplant
Acute rejection rates are extremely common in the first year after lung 
transplantation with approximately 30–40% of recipients having at least one 
episode in the first year after transplant. Triple-drug immunosuppressive agents 
have become the standard of care and are prescribed to minimize this risk [37]. 
Immunosuppressive dosing must be carefully considered so as to minimize acute 
rejection risk without leading way to infections. The regimen typically prescribed 
in lung and most solid organ transplants typically includes prednisone, a calcineu-
rin inhibitor (tacrolimus or cyclosporine), and an antimetabolite (azathioprine 
or mycophenolate mofetil). Despite the unique side effects of each of these drug 
classes, the cumulative effect of immunosuppression may predispose individuals to 
opportunistic infections, renal failure, malignancies, posttransplant hypertension, 
diabetes, and dyslipidemia. Table 1 reviews common drug interactions that can 
alter immunosuppressant clearance or therapeutic drug levels.
The lung allograft is subject to a variety of insults resulting in various paren-
chymal abnormalities. These complications are broadly classified as infectious and 
noninfectious. The development of infections is the leading cause of morbidity and 
mortality in the first 3 years following lung transplantation [38]. Bacterial patho-
gens are the most common, but fungal and viral infections are also particularly 
important (especially Aspergillus and Cytomegalovirus).
Despite their ubiquitous and potentially ominous nature, radiographic pulmo-
nary parenchymal abnormalities predicting posttransplant complication can be 
nonspecific (Figures 3–5). Bacterial and fungal radiographic features are highly 
varied and include consolidation, ill-defined nodules, cavitation, and ground-glass 
opacifications, making them difficult to identify. Viral infections (especially CMV) 
may have normal radiographs. They can also show ground-glass, micronodules, 
consolidation, and/or reticulonodular opacities.
Moreover, acute cellular rejection (ACR) can present similar to any of the previ-
ously mentioned complications. ACR radiographic features can appear as normal 
radiograph, ground-glass opacities, alveolar opacities, consolidation, nodules, as 
well as a new or evolving pleural effusion (seen in 43% of patients) [39, 40].
Due to the radiographic overlap in postoperative lung pathologies, broad-
spectrum antimicrobial therapy is often instituted in the acutely ill lung transplant 
Figure 3. 
Chest X-ray of a single-lung transplant recipient for IPF.
Interstitial Lung Diseases
46
recipient. A broad infectious differential must be maintained given the triple-drug 
immunosuppression when considering treatment options. Similarly, acute rejection 
is on the differential, and differentiating between the two is imperative. Clinical 
correlation and transbronchial biopsy are often indicated for discerning the diagno-
sis. The number of acute cellular rejections and infections contribute to a higher risk 
of developing chronic rejection.
Primary graft dysfunction (PGD) accounts for the main cause of death within 
the first 30 days following lung transplantation [38]. The underlying diagnosis lead-
ing to transplant is not predictive of developing PGD (restrictive disease with PGD 
22.1% vs. without PGD 20.3%) [37]. More recently, patients with IPF and associated 
pulmonary hypertension have been shown to have a higher incidence of developing 
PGD [41]. Moreover, higher pulmonary artery pressures impart a greater risk of 
developing severe PGD (grade 3).
Early diagnosis and management may impart a lower incidence of chronic 
allograft rejection. Chronic allograft rejection manifests as bronchiolitis 
Figure 5. 
Chest X-ray of a single right-lung transplant recipient for LAM.
Figure 4. 
Chest X-ray of a bilateral-lung transplant recipient for IPF.
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obliterans syndrome (BOS) or restrictive allograft syndrome (RAS). BOS is 
typically a progressive airflow limitation demonstrated on pulmonary function 
testing (PFT). Grading of BOS depends on the severity of airflow limitation 
relative to the patient’s best posttransplant FEV1. The radiographic presentations 
of BOS include a mixture of hypo- and hyperattenuation (mosaic attenuation) 
regions produced by air trapping and decreased peripheral vascularity, bronchi-
ectasis, and subsegmental atelectasis. RAS is hallmarked by upper lobe fibrosis. 
Radiographic RAS may have reticulonodular opacities, honeycombing, traction 
bronchiectasis, loss of lung volume, and interlobular septal thickening  
(Figure 6). In comparison to BOS however, these patients have restrictive  
physiology on PFTs [40, 42].
By bronchoscopy, the presence of eosinophilia and neutrophilia, airway infec-
tion and/or colonization, and acute cellular/lymphocytic bronchiolitis all impart 
increased risk of developing both BOS and RAS [37]. The underlying pathology 
necessitating transplant does not seem to influence the development of one form of 
chronic allograft rejection (24% BOS and 20.8% RAS).
Altering medications within therapeutic classes or augmenting existing therapy 
has been advocated when patients develop chronic rejection. There is clearly a 
small subset of patients who derive benefit from this therapy. However, alteration 
of immunosuppression may also increase the risk of opportunistic infections and 
development malignancy.
One alternative therapy for BOS is chronic azithromycin. Several small case 
series as well as one prospective, randomized, double-blind, placebo-controlled 
trial have suggested a benefit with azithromycin in lung transplant recipients 
[43–45]. Azithromycin may prevent the development of BOS, as well as treat a 
subset of patients with BOS. The mechanism for the positive effect of azithromycin 
in BOS prevention and treatment is believed to be related to its anti-inflammatory 
properties. Chronic azithromycin therapy is well tolerated. Gastrointestinal side 
effects, QTc prolongation, and auditory disturbances are common side effects. 
Clinicians should be aware that this medication is often taken chronically in lung 
transplant patients when considering antibiotic choices for acute respiratory infec-
tions in this population.
Figure 6. 
CT chest for a bilateral-lung transplant recipient for sarcoidosis in chronic allograft rejection.
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Currently, the bronchial anastomosis is created in an “end-to-end” fashion, 
and bronchial artery circulation is lost. Thus, the donor bronchus and anasto-
mosis depend solely on the poorly oxygenated pulmonary artery, portending 
to the development of local ischemia. Early complications (<3 months) from 
airway/anastomotic ischemia include necrosis and wound dehiscence. During 
the healing and remodeling phase (>3 months), typical complications are 
airway stenosis, granulation tissue accumulation, and malacia (typically a later 
occurrence). Graft rejection, immunosuppression, and bronchopulmonary 
infections have also been associated with airway complications. Lung transplant-
associated airway complications manifest in up to 30% of patients [46, 47]. 
Management strategies include airway dilation with silicone or self-expandable 
metallic stents, cryoablation, and laser photoresection. Airway stents are gener-
ally placed when respiratory symptoms are refractory to the abovementioned 
modalities (Figure 7). Most patients experience improvement in symptoms and 
lung function. However, complications from the above interventions include 
mucus plugging, obstructive granuloma, stent migration, fracture, or infectious 
colonization.
7.3 Complications of native lung in single-lung transplantation
It bears mention that patients’ native lung disease progression is not halted 
with the contralateral lung transplantation despite robust immunosuppression. 
The amount of native lung ground-glass opacification or fibrosis does not change 
or increases for the majority of single-lung transplant recipients with IPF [48]. 
Patients with IPF lose 10.8% of native lung volume and have an 11% increase in 
fibrosis in the first 4 years following SLT [49]. Up to 52% of the native lungs had 
evidence of fibrosis at the time of transplant, and this number grows to 92% at 
4 years posttransplant.
Common complications reported in IPF patients following SLT include bacterial 
or fungal infections, retention of secretions with associated airway obstruction 
and atelectasis, as well as pneumothoraces [50]. Moreover, posttransplant acute 
exacerbation of IPF is increasingly recognized [51]. Bronchogenic carcinomas 
have been reported at higher rates in single-lung transplant recipients. Significant 
Figure 7. 
Silicone endobronchial stent placed in a patient with anastomotic stricture development.
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contributing risk factors include advanced recipient or donor age, smoking history 
(>60 pack years), and COPD or IPF as the underlying lung disease [52].
7.4 Thromboembolic events following lung transplantation
Deep vein thrombus (DVT) and pulmonary emboli (PE) occur in up to 29% 
of lung transplant recipients. Two-thirds of these events occur in the first year 
of transplantation, and 20% of these events develop within the first month. 
Reduced mobility and recent surgery are risk factors. Inflammation also inhibits 
anticoagulant factors [53]. Other risk factors include, most notably, an underly-
ing diagnosis of IPF. Male gender, advanced age, pneumonia, diabetes mellitus, 
and utilization of cardiopulmonary bypass are other well-defined risk factors 
[41, 54]. Most of the pulmonary emboli occur within the allograft (86%)  
[54, 55].
The intrinsically thrombogenic surface of the allograft vasculature anas-
tomosis and increased allograft perfusion with concurrent drop in pulmonary 
vascular resistance in single-lung transplant recipients are postulated predilec-
tions for allograft predominant clot formation. Notably, clots can still occur in 
the native lung. Most posttransplant PEs are 5.8 months following lung trans-
plantation. Many centers advocate prophylactic anticoagulation for 6–9 months 
following transplant for this reason. Luckily, most patients tolerate an embolic 
event, even in the presence of large clot burden, without a loss of lung allograft 
function [56].
8. Conclusion
Lung transplantation is an important treatment option for patients with inter-
stitial lung disease after medical therapy has failed. However, pulmonary fibrosis 
patients have the worst survival following lung transplantation. Nonetheless, there 
is a survival advantage for those with pulmonary fibrosis who proceed with lung 
transplant [57, 58]. Moreover, lung transplantation improves quality of life. ISHLT 
registry data denotes that lung transplant recipients have better quality of life, 
general health, and many are even able return to work. Up to 30% of patients are 
working at 1 year, and 50% are working at 5 years [59–62].
Lung transplantation, however, is not without its risks, and patient awareness 
of these risks is important before lung transplantation is entertained or pursued. 
All appropriate measures should be taken to mitigate risk factors surrounding lung 
transplantation. So doing can potentially improve long-term outcomes. Lastly, as a 
growing number of lung transplant recipients make their way into the community, 
the onus for and access to working lung transplant knowledge now extend far 
beyond the transplant center, into our communities at large.
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Abstract
Idiopathic pulmonary fibrosis (IPF) is known as one of the most severe lung 
conditions and the worst form of interstitial lung disease (ILD). There is a continu-
ing concern about clinical research to identify new therapies that influence the 
quality of life in patients diagnosed with this chronic progressive pulmonary disease, 
with an average survival of 3–5 years. Although in recent years great progress has 
been made to slow down the functional decline of the disease with new antifibrotic 
therapies, it has failed to alter the prognosis and survival of IPF patients. Clinical tri-
als and recent ATS/ERS guidelines have brought at least moderate and low levels of 
evidence for increased effort tolerance, decreased symptoms, and improved quality 
of life following participation in lung rehabilitation programs for ILD patients and in 
particular those with IPF. Pulmonary rehabilitation has been shown to be a standard 
of care for COPD patients, but their personalized application to patients with IPF has 
had positive short-term results, becoming a safe alternative to non-pharmacological 
treatment. The chapter includes the general objectives of rehabilitation programs, 
their type and structure, ways of complex assessment of patients before and after a 
training exercise, types of exercises, and short- and long-term results.
Keywords: idiopathic pulmonary fibrosis (IPF), pulmonary rehabilitation  
program (PRP), physical activity, exercise training, quality of life
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic disease that affects exclusively 
the lung, with an unknown etiology and a fast-progressive irreversible evolution, 
therefore disabling the adult. For most of the patients, the average survival is 
approximately 3–5 years from diagnosis [1, 2]. With an unpredictable but progres-
sive evolution (slower, stable, or accelerated decline from patient to patient), the 
disease is characterized by a chronic presence of symptoms, specifically the exer-
tional dyspnea, low tolerance to effort, and the deterioration of the quality of life 
[1–4]. The diagnosis of the disease is often delayed and not reported until advanced 
stages [5]. A hope to halt the progression of the disease occurred with the dem-
onstration of the reduction in the functional decline of the new pharmacological 
agents, pirfenidone and nintedanib, without claiming to cure the disease [1–5]. IPF 
remains a life-threatening illness in which the patient is fighting for survival as long 
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conditions and the worst form of interstitial lung disease (ILD). There is a continu-
ing concern about clinical research to identify new therapies that influence the 
quality of life in patients diagnosed with this chronic progressive pulmonary disease, 
with an average survival of 3–5 years. Although in recent years great progress has 
been made to slow down the functional decline of the disease with new antifibrotic 
therapies, it has failed to alter the prognosis and survival of IPF patients. Clinical tri-
als and recent ATS/ERS guidelines have brought at least moderate and low levels of 
evidence for increased effort tolerance, decreased symptoms, and improved quality 
of life following participation in lung rehabilitation programs for ILD patients and in 
particular those with IPF. Pulmonary rehabilitation has been shown to be a standard 
of care for COPD patients, but their personalized application to patients with IPF has 
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1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic disease that affects exclusively 
the lung, with an unknown etiology and a fast-progressive irreversible evolution, 
therefore disabling the adult. For most of the patients, the average survival is 
approximately 3–5 years from diagnosis [1, 2]. With an unpredictable but progres-
sive evolution (slower, stable, or accelerated decline from patient to patient), the 
disease is characterized by a chronic presence of symptoms, specifically the exer-
tional dyspnea, low tolerance to effort, and the deterioration of the quality of life 
[1–4]. The diagnosis of the disease is often delayed and not reported until advanced 
stages [5]. A hope to halt the progression of the disease occurred with the dem-
onstration of the reduction in the functional decline of the new pharmacological 
agents, pirfenidone and nintedanib, without claiming to cure the disease [1–5]. IPF 
remains a life-threatening illness in which the patient is fighting for survival as long 
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as possible, striving to cope with the symptoms and the noticeable fatigue. Given 
that this is a fatal disease, some of the needs identified in patients with IPF and their 
families are easy access to information and IPF specialists, the existence of more 
treatment methods, emotional support, and access to end-of-life care [3].
The indication of pulmonary rehabilitation (PR) for patients with IPF came 
from the positive results stemming from the exercise training program (ETP) in 
COPD. Thus, numerous clinical studies performed on patients with IPF proved that 
their health and wellness could be improved, at least for short periods, through ETP 
which are personalized and supervised by specialists [2].
Pulmonary rehabilitation program (PRP) is an evidence-based recommenda-
tion for the non-pharmacological treatment of patients with chronic pulmonary 
diseases, especially for COPD, but also for interstitial lung diseases [1, 4]. PRP must 
be included in the integrative treatment of IPF, taking into consideration the sever-
ity of the disease, high mortality during exacerbations, a modest response to new 
drugs, and accelerated deterioration of lung function.
2.  The indication of pulmonary rehabilitation starting from 
pathophysiology in IPF
The usual interstitial pneumonia (UIP) pattern (fibrosis with collagen and 
matrix deposition, the presence of fibroblastic foci and alveolar collapse, pulmo-
nary heterogeneous architectural distortion and honeycombing presence) deter-
mines the main pathophysiological changes in IPF: loss of lung volume, decreased 
lung compliance, abnormal pulmonary gas exchange with oxygen diffusion limita-
tion, low mixed venous oxygen content, circulatory impairments, and alveolar 
ventilation/perfusion (V′A/Q′) mismatching [6, 7].
Pulmonary function tests reveal restrictive pulmonary dysfunction, indirect 
signs of increased elastic recoil, and decrease in diffusion capacity for carbon mon-
oxide (DLCO). Pulse oximetry and arterial blood gases reveal hypoxemia initially 
only during exercise and, in advanced cases, as well during resting [2, 7]. Patients 
with IPF have reduced maximal or peak oxygen uptake (V’O2peak), peak work rate, 
and submaximal exercise endurance [7].
The progressive installation of morphophysiopathological changes is reflected 
in the clinical symptoms of patients. The exertional dyspnea is the first and most 
important symptom of IPF patients. The more advanced the disease, the more 
severe the dyspnea is. The patients tend to be less physically active and more 
depressed [8]. The level of dyspnea is strongly correlated with the exercise capacity, 
the quality of life, and mortality [1, 8, 9]. Other associated symptoms are fatigue, 
dry cough, chest discomfort, and leg pain. These symptoms are mild or inconsistent 
at the beginning of the disease, but they get worse over time and lead to an impair-
ment of daily activities [10]. Symptomology and physical inactivity are directly 
related to depression, quality of life (QoL), and increased mortality [10, 11].
Consequently, the most important mechanisms that limit effort capacity and 
change the IPF patient’s lifestyle, into a sedentary one, are inefficient breathing 
mechanics, abnormal pulmonary gas exchange, circulatory impairment, and 
exercise-induced hypoxemia [1, 7, 12, 13]. In time, progressive exercise-induced 
hypoxemia leads to respiratory and skeletal muscle dysfunction [1, 7]. Non-
pharmacological interventions must take into account these mechanisms and create 
programs that seek to influence the patients’ outcomes positively. PR is a safe and 
effective non-pharmacological treatment [14].
The official ERS/ARS statement define pulmonary rehabilitation as “Pulmonary 
rehabilitation is a comprehensive intervention based on a thorough patient 
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assessment followed by patient tailored therapies that include, but are not limited 
to, exercise training, education, and behavior change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease and 
to promote the long-term adherence to health-enhancing behaviors” [11].
PR decreases dyspnea, improves exercise capacity, and helps to cope with 
functional activities of daily life in IPF patients, even though the significance of 
these benefits is smaller and lasts for less time than in other chronic lung disease like 
COPD [15–20].
3. General objectives of pulmonary rehabilitation in IPF
• Decreasing symptoms, especially dyspnea
• Increasing effort capacity
• Enhancing the quality of life, health, and wellness
• Improving muscle strength and endurance
• Maintaining joint mobility
• Increasing tolerance to physical activity with the improved cardiometabolic 
and respiratory profile
• Improving well-being and cognitive functions
• Decreasing depression and anxiety
• Offer social and psychological support with the possibility of occupational and 
group therapy
• Promoting pro-healthy behaviors, with decreasing effort deconditioning
• Self-management of the disease [20–22]
The adaptation of pulmonary rehabilitation programs for IPF started from those 
applied to patients with COPD. It is advised to take into account the pathophysiol-
ogy mechanisms particular to IPF and the clinical particularities of these patients. 
Patients have a respiratory pattern of frequent, superficial, and rapid breaths that 
worsen during exercise [7, 17, 18]. The frequent association of pulmonary hyperten-
sion (PH) aggravates the symptoms [1, 4]. An explanation for the positive results 
of PRP could be that repetitive ventilator stimulus during physical training sessions 
increases chest expansion and secondary pleural elasticity and pulmonary compli-
ance while also improving V’A/Q‘ mismatch, increasing V’O2peak [13, 23]. Also, deep 
breathing exercises with stretching and the training of respiratory muscles, includ-
ing the diaphragm, can help to reduce dyspnea [20, 23, 24].
4. Assessment of IPF patients before and after PRP
Before entering into a PRP, patients with IPF need to be assessed by the multidis-
ciplinary team regarding clinical and functional status, imaging, effort tolerance, 
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as possible, striving to cope with the symptoms and the noticeable fatigue. Given 
that this is a fatal disease, some of the needs identified in patients with IPF and their 
families are easy access to information and IPF specialists, the existence of more 
treatment methods, emotional support, and access to end-of-life care [3].
The indication of pulmonary rehabilitation (PR) for patients with IPF came 
from the positive results stemming from the exercise training program (ETP) in 
COPD. Thus, numerous clinical studies performed on patients with IPF proved that 
their health and wellness could be improved, at least for short periods, through ETP 
which are personalized and supervised by specialists [2].
Pulmonary rehabilitation program (PRP) is an evidence-based recommenda-
tion for the non-pharmacological treatment of patients with chronic pulmonary 
diseases, especially for COPD, but also for interstitial lung diseases [1, 4]. PRP must 
be included in the integrative treatment of IPF, taking into consideration the sever-
ity of the disease, high mortality during exacerbations, a modest response to new 
drugs, and accelerated deterioration of lung function.
2.  The indication of pulmonary rehabilitation starting from 
pathophysiology in IPF
The usual interstitial pneumonia (UIP) pattern (fibrosis with collagen and 
matrix deposition, the presence of fibroblastic foci and alveolar collapse, pulmo-
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mines the main pathophysiological changes in IPF: loss of lung volume, decreased 
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ventilation/perfusion (V′A/Q′) mismatching [6, 7].
Pulmonary function tests reveal restrictive pulmonary dysfunction, indirect 
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the quality of life, and mortality [1, 8, 9]. Other associated symptoms are fatigue, 
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ment of daily activities [10]. Symptomology and physical inactivity are directly 
related to depression, quality of life (QoL), and increased mortality [10, 11].
Consequently, the most important mechanisms that limit effort capacity and 
change the IPF patient’s lifestyle, into a sedentary one, are inefficient breathing 
mechanics, abnormal pulmonary gas exchange, circulatory impairment, and 
exercise-induced hypoxemia [1, 7, 12, 13]. In time, progressive exercise-induced 
hypoxemia leads to respiratory and skeletal muscle dysfunction [1, 7]. Non-
pharmacological interventions must take into account these mechanisms and create 
programs that seek to influence the patients’ outcomes positively. PR is a safe and 
effective non-pharmacological treatment [14].
The official ERS/ARS statement define pulmonary rehabilitation as “Pulmonary 
rehabilitation is a comprehensive intervention based on a thorough patient 
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assessment followed by patient tailored therapies that include, but are not limited 
to, exercise training, education, and behavior change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease and 
to promote the long-term adherence to health-enhancing behaviors” [11].
PR decreases dyspnea, improves exercise capacity, and helps to cope with 
functional activities of daily life in IPF patients, even though the significance of 
these benefits is smaller and lasts for less time than in other chronic lung disease like 
COPD [15–20].
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• Increasing effort capacity
• Enhancing the quality of life, health, and wellness
• Improving muscle strength and endurance
• Maintaining joint mobility
• Increasing tolerance to physical activity with the improved cardiometabolic 
and respiratory profile
• Improving well-being and cognitive functions
• Decreasing depression and anxiety
• Offer social and psychological support with the possibility of occupational and 
group therapy
• Promoting pro-healthy behaviors, with decreasing effort deconditioning
• Self-management of the disease [20–22]
The adaptation of pulmonary rehabilitation programs for IPF started from those 
applied to patients with COPD. It is advised to take into account the pathophysiol-
ogy mechanisms particular to IPF and the clinical particularities of these patients. 
Patients have a respiratory pattern of frequent, superficial, and rapid breaths that 
worsen during exercise [7, 17, 18]. The frequent association of pulmonary hyperten-
sion (PH) aggravates the symptoms [1, 4]. An explanation for the positive results 
of PRP could be that repetitive ventilator stimulus during physical training sessions 
increases chest expansion and secondary pleural elasticity and pulmonary compli-
ance while also improving V’A/Q‘ mismatch, increasing V’O2peak [13, 23]. Also, deep 
breathing exercises with stretching and the training of respiratory muscles, includ-
ing the diaphragm, can help to reduce dyspnea [20, 23, 24].
4. Assessment of IPF patients before and after PRP
Before entering into a PRP, patients with IPF need to be assessed by the multidis-
ciplinary team regarding clinical and functional status, imaging, effort tolerance, 
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quality of life, physical activities of daily living (PADL), the presence of comorbidi-
ties, needs, and expectations from the pharmacological treatment. The evaluation of 
comorbidities such as coronary arterial disease, systemic and pulmonary hyperten-
sion, right and left ventricle dysfunction, and arrhythmias during exercise is critical. 
The additional impairment of the cardiovascular system decreases the effort capacity 
and worsens dyspnea and prognosis of patients [1, 2, 25]. This complex assessment 
also has the role in determining the type, intensity, and results of the PRP.
4.1 Symptoms assessment
Dyspnea is the most significant and disabling symptom for IPF patients. It can 
be objectively identified before, in the end, and at any time within PRP and can 
modulate the intensity of exercise. In studies targeting PR in IPF, dyspnea is quanti-
fied using one of the following scales:
4.1.1 Modified Medical Research Council (MMRC)
The Modified Medical Research Council (MMRC) scale is a well-known tool which 
assesses the dyspnea based on 5 degrees that are reported by the patient depending 
on his physical activity tolerance. It seems that dyspnea severity correlates with lung 
function parameters and Saint George Respiratory Questionnaire (SGRQ). The patient 
identifies the number that best matches his/her shortness of breath [26–28]. The 
standardized mean difference (SMD) for change in dyspnea in favor of exercise train-
ing (ET) is considered to be −0.66 (95% CI=1.05-0.28) [15]. MMRC dyspnea scales 
reflect the severity of the limitation of daily activity, pulmonary function, and quality 
of life and correlate with mortality. It can replace, where it is not possible to asses, the 
peripheral muscle strength, functional exercise capacity, and ADL performance [29].
4.1.2  University of California, San Diego Shortness of Breath Questionnaire 
(UCSD SOB)
The University of California, San Diego Shortness of Breath Questionnaire (UCSD 
SOB) uses a 24 questions questionnaire about the level of dyspnea during daily 
activities [30]. Five points represent a significant mean difference [31]. Dyspnea 
measured by UCSD SOB showed the strongest correlations with 6MWD [32].
4.1.3 Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI)
The Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) assesses on a 
5-degree scale (from 0 to 4), the daily dyspnea level in response to three categories 
of questions on functional impairment, the magnitude of task, and the magnitude 
of effort [26, 33, 34]. TDI records the changes from the initial value, the total score 
varying between −9 (worsening) and +9 (improvement). The significant minimal 
difference between TDI is 1 point [33, 34].
4.1.4 Modified Borg Scale (MBS)
The Modified Borg Scale (MBS) has 10 points (from 0 to 10), where participants 
choose descriptive terms that best suit their current state (0 = no dyspnea, 5 = moderate 
dyspnea, 10 = very severe dyspnea). It is used before and after performing a submaxi-
mal effort test such as 6MWT. The standardized significant mean difference (SMD) 
for change is 1 point [31]. During exercise training sessions in the PRP, the Borg scale is 
used as an essential tool to recommend workload [35].
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It was shown that there are correlations between clinical dyspnea rating and 
exercise capacity, exercised gas exchange and exercise capacity, and SGRQ in 
patients with IPF [26, 29, 36].
4.2 Pulmonary function tests
Pulmonary function tests, including forced vital capacity (FVC), total lung 
capacity (TLC), maximal voluntary ventilation (FEV1 x 35), and diffusion capac-
ity for carbon monoxide (DLCO), are important for stratifying the severity of the 
patient’s condition, but generally, PRP does not significantly influence the results 
of these tests [20]. The severity of dysfunction may guide the type and intensity 
of physical exercise and may be a warning about the risk of adverse effects (severe 
hypoxemia, hypotension, arrhythmias, etc.)
4.3 Standardized effort tests
Standardized effort tests are important for choosing the intensity of training 
programs.
4.3.1 The 6-minute walking test (6MWT)
The 6-minute walking test (6MWT) is a simple and safe tool used for IPF patients, 
where the subject moves in his rhythm [37]. It is performed according to ATS guide-
lines in a 30-m corridor [38]. 20–30 min of rest is recommended before and after the 
6MWD test. The blood pressure, heart rate, respiratory frequency, oxygen satura-
tion (SpO2), the severity of dyspnea, and fatigue are assessed by the modified Borg 
scale [38, 39]. SpO2 is recorded in the sitting position. It is recommended that the 
6MWD test be performed with a SpO2 Holter, to record the length of the desatura-
tion and the lowest value of oxygen [40]. It is always necessary to take into consider-
ation the contraindications of walking tests and also the indications of interruption 
of the test. An important cessation criterion is a desaturation below 85% or tachycar-
dia [80% of the theoretical maximum heart rate ( 220−age )], a situation easily met 
in IPF patients [1, 41]. The distance covered by the patient in 6 minutes is compared 
with the predicted value estimated by the formulas (women: 493 + (2.2 × height 
(cm)) − (0.93 × G (kg)) − 5.3 × age (years) and for the male + 17 m). The lower limit 
of normal 6MWD is the theoretical distance minus 100 m [42–44]. The 6-minute 
walk test distance (6MWD) does not correlate with sex, age, body mass index, and 
other medical comorbidities, but it is an independent predictor of survival rate, bet-
ter than FVC and DLCO [37]. The 12-minute walk test is less used for IPF patients 
because it requires greater effort.
The minimal clinical important significant difference (MCID) for 6MWD varies 
with the author, but a change of approximately 30 m is considered to be significant 
in IPF patients [32, 41, 44, 45].
4.3.2 Cardiopulmonary exercise tests
Cardiopulmonary exercise tests, when available, provide details on the mechanisms 
of effort intolerance. Measures of the anaerobic threshold, peak oxygen consump-
tion (V′O2peak), and peak work rate (WR) are essential for determining the intensity 
of PRP and for assessing the benefits in dynamics. The SpO2, blood pressure, and 
12-lead electrocardiogram are also recorded during these tests [46]. Cardiopulmonary 
stress tests are the gold standard for assessing the effort intolerance due to either 
lung, cardiac, or musculoskeletal pathologies. It is performed with a cycle ergometer 
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quality of life, physical activities of daily living (PADL), the presence of comorbidi-
ties, needs, and expectations from the pharmacological treatment. The evaluation of 
comorbidities such as coronary arterial disease, systemic and pulmonary hyperten-
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The additional impairment of the cardiovascular system decreases the effort capacity 
and worsens dyspnea and prognosis of patients [1, 2, 25]. This complex assessment 
also has the role in determining the type, intensity, and results of the PRP.
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be objectively identified before, in the end, and at any time within PRP and can 
modulate the intensity of exercise. In studies targeting PR in IPF, dyspnea is quanti-
fied using one of the following scales:
4.1.1 Modified Medical Research Council (MMRC)
The Modified Medical Research Council (MMRC) scale is a well-known tool which 
assesses the dyspnea based on 5 degrees that are reported by the patient depending 
on his physical activity tolerance. It seems that dyspnea severity correlates with lung 
function parameters and Saint George Respiratory Questionnaire (SGRQ). The patient 
identifies the number that best matches his/her shortness of breath [26–28]. The 
standardized mean difference (SMD) for change in dyspnea in favor of exercise train-
ing (ET) is considered to be −0.66 (95% CI=1.05-0.28) [15]. MMRC dyspnea scales 
reflect the severity of the limitation of daily activity, pulmonary function, and quality 
of life and correlate with mortality. It can replace, where it is not possible to asses, the 
peripheral muscle strength, functional exercise capacity, and ADL performance [29].
4.1.2  University of California, San Diego Shortness of Breath Questionnaire 
(UCSD SOB)
The University of California, San Diego Shortness of Breath Questionnaire (UCSD 
SOB) uses a 24 questions questionnaire about the level of dyspnea during daily 
activities [30]. Five points represent a significant mean difference [31]. Dyspnea 
measured by UCSD SOB showed the strongest correlations with 6MWD [32].
4.1.3 Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI)
The Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) assesses on a 
5-degree scale (from 0 to 4), the daily dyspnea level in response to three categories 
of questions on functional impairment, the magnitude of task, and the magnitude 
of effort [26, 33, 34]. TDI records the changes from the initial value, the total score 
varying between −9 (worsening) and +9 (improvement). The significant minimal 
difference between TDI is 1 point [33, 34].
4.1.4 Modified Borg Scale (MBS)
The Modified Borg Scale (MBS) has 10 points (from 0 to 10), where participants 
choose descriptive terms that best suit their current state (0 = no dyspnea, 5 = moderate 
dyspnea, 10 = very severe dyspnea). It is used before and after performing a submaxi-
mal effort test such as 6MWT. The standardized significant mean difference (SMD) 
for change is 1 point [31]. During exercise training sessions in the PRP, the Borg scale is 
used as an essential tool to recommend workload [35].
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It was shown that there are correlations between clinical dyspnea rating and 
exercise capacity, exercised gas exchange and exercise capacity, and SGRQ in 
patients with IPF [26, 29, 36].
4.2 Pulmonary function tests
Pulmonary function tests, including forced vital capacity (FVC), total lung 
capacity (TLC), maximal voluntary ventilation (FEV1 x 35), and diffusion capac-
ity for carbon monoxide (DLCO), are important for stratifying the severity of the 
patient’s condition, but generally, PRP does not significantly influence the results 
of these tests [20]. The severity of dysfunction may guide the type and intensity 
of physical exercise and may be a warning about the risk of adverse effects (severe 
hypoxemia, hypotension, arrhythmias, etc.)
4.3 Standardized effort tests
Standardized effort tests are important for choosing the intensity of training 
programs.
4.3.1 The 6-minute walking test (6MWT)
The 6-minute walking test (6MWT) is a simple and safe tool used for IPF patients, 
where the subject moves in his rhythm [37]. It is performed according to ATS guide-
lines in a 30-m corridor [38]. 20–30 min of rest is recommended before and after the 
6MWD test. The blood pressure, heart rate, respiratory frequency, oxygen satura-
tion (SpO2), the severity of dyspnea, and fatigue are assessed by the modified Borg 
scale [38, 39]. SpO2 is recorded in the sitting position. It is recommended that the 
6MWD test be performed with a SpO2 Holter, to record the length of the desatura-
tion and the lowest value of oxygen [40]. It is always necessary to take into consider-
ation the contraindications of walking tests and also the indications of interruption 
of the test. An important cessation criterion is a desaturation below 85% or tachycar-
dia [80% of the theoretical maximum heart rate ( 220−age )], a situation easily met 
in IPF patients [1, 41]. The distance covered by the patient in 6 minutes is compared 
with the predicted value estimated by the formulas (women: 493 + (2.2 × height 
(cm)) − (0.93 × G (kg)) − 5.3 × age (years) and for the male + 17 m). The lower limit 
of normal 6MWD is the theoretical distance minus 100 m [42–44]. The 6-minute 
walk test distance (6MWD) does not correlate with sex, age, body mass index, and 
other medical comorbidities, but it is an independent predictor of survival rate, bet-
ter than FVC and DLCO [37]. The 12-minute walk test is less used for IPF patients 
because it requires greater effort.
The minimal clinical important significant difference (MCID) for 6MWD varies 
with the author, but a change of approximately 30 m is considered to be significant 
in IPF patients [32, 41, 44, 45].
4.3.2 Cardiopulmonary exercise tests
Cardiopulmonary exercise tests, when available, provide details on the mechanisms 
of effort intolerance. Measures of the anaerobic threshold, peak oxygen consump-
tion (V′O2peak), and peak work rate (WR) are essential for determining the intensity 
of PRP and for assessing the benefits in dynamics. The SpO2, blood pressure, and 
12-lead electrocardiogram are also recorded during these tests [46]. Cardiopulmonary 
stress tests are the gold standard for assessing the effort intolerance due to either 
lung, cardiac, or musculoskeletal pathologies. It is performed with a cycle ergometer 
Interstitial Lung Diseases
60
or treadmill, but there is also a portable metabolic device. Cycle ergometry is the 
preferred method of being safer, with few movement artifacts, allowing a constant 
increase in workload, and is slightly influenced by weight [46–48]. Treadmill testing 
involves a kind of effort more common to patient’s daily activities (walking and run-
ning) and can train more muscle mass. Therefore, the V′O2peak is 5–10% higher than in 
cyclo-ergometry. Effort tests have a role in selecting patients for PRP and establishing 
rehabilitation design protocols, as well as evaluating outcomes [48].
In patients with advanced IPF, it is not always possible to perform cyclo-ergome-
try. Volitional fatigue or increased oxygen desaturation (SpO2 < 80%) is quickly 
reached, and dizziness or mental confusion may also occur within 10–12 min of 
effort [48]. The incremental exercise testing shows decreased aerobic capacity 
(V′O2peak ~ 62% from predicted) and reduced maximal achievable workload in 
ILD. Other changes in IPF patients such as inefficient ventilation, desaturation, gas 
exchange abnormalities, circulator, and skeletal muscle dysfunction are reported 
[2]. These changes provoke a downward spiral of hypoxia, limited exercise capacity, 
deconditioning, shallow breathing pattern, and pulmonary hypertension [48].
4.4 Doppler-echocardiographic assessment
Doppler-echocardiographic assessment of pulmonary artery systolic pressure 
should be assessed because a significant percentage of the IPF patients develop 
PH from early stages of the disease [10, 49]. It represents an important prognostic 
parameter [10, 49]. It usually replaces right heart catheterization, echocardiogra-
phy being a noninvasive and widely available tool for screening PH. A substantial 
desaturation during exercise or a disproportionate exercise limitation related to the 
degree of lung restriction will increase the suspicion of PH [7, 10].
4.5  Chest high-resolution computed tomography (HRCT) and  
lung ultrasound
HRCT is the essential method to diagnose IPF. If the HRCT shows a pattern of 
usual interstitial pneumonia (UIP), this being the most characteristic to IPF, then 
its presence avoids invasive procedure such as lung biopsy. In the last few years, 
radiation-free techniques, such as the lung ultrasound, appear to be very sensitive 
in detecting fibrotic change or monitoring disease progression [50]. Imaging on 
HRCT is important and significant before a PRP, but its rehabilitation benefits are 
not assessed according to the initial findings.
4.6 Physical activity of daily living (PADL)
Physical activity of daily living (PADL) has a major impact on the quality of life 
and well-being of IPF patients and needs to be evaluated. PADL refers to volunteer 
movements that the patient performs at home, during professional or recreational 
activities that are energy-consuming. There is an inversely proportional relationship 
between PADL and sedentariness, reduced autonomy, disability, risk of hospital-
ization, and death [51]. Besides, the disease severity (dyspnea levels, SpO2 < 88%, 
DLCO < 40%, 6MWD, the extent of honeycombing on computed tomography, level 
of PH) was associated with lower physical activity among patients’ stable IPF [52].
4.6.1 PADL assessment
PADL assessment is performed either by direct observation (time and staff 
consuming because it is individually applied), energy expenditure (for research 
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calorimetry), questionnaires, and other devices with motion sensors (detect move-
ment and quantify PADL: pedometers, accelerometers, or physical activity monitors). 
The questionnaires are subjective methods of evaluating the effects of the symptoms 
on the patient’s daily activities and quality of life, and they are instruments that are 
used in evaluating PRP [53]. Achieving progress through training programs can 
motivate the patient to pursue an active lifestyle for as long as possible. Pedometers 
measure only the distance covered daily (10,000 steps/day for a healthy lifestyle in 
the general population), but the effort intensity is better quantified by accelerometers 
[54]. These are preferred in sedentary or disabled patients, being more sensitive to the 
detection and description of movements. Daily activity can be quantified using  
the activity monitor for at least seven consecutive days from awakening to bed [2]. 
The intensity of physical activity is evaluated on a scale of 1–5, depending on the 
energy expenditure, expressed in the metabolic equivalent task (METS) [55].
4.6.2 The questionnaires used in PADL evaluation
The questionnaires used in PADL evaluation for IPF are easy to apply, cheap, 
self-administered, validated (internal consistency and test-retest reliability) and 
correlate with the estimated energy consumption by the methods mentioned above. 
The most commonly used questionnaires in clinical studies, which are extrapolated 
to IPF patients, are as follows:
4.6.2.1  Self-report 7-day short form International Physical Activity Questionnaire 
(IPAQ )
Self-report 7-day short form International Physical Activity Questionnaire (IPAQ ) 
[2, 56] consists of nine items which evaluate the level of physical activity that is 
quantified in METS for the effort intensity: vigorous (8 METS), moderate  
(4 METS), walking (3.3 METS), and sitting times. The total score is the sum of all 
types of activities (the number of minutes spent/day) multiplied by the level of 
energy (MET) and multiplied by the amount of time spent/week [(MET)-min/week] 
[55]. An active patient is considered to perform 600 METS-min/week (150 min/
week × 4METS moderate intensity activity) [54, 57]. IPAQ ≤ 417 (MET-min/week) 
∆SpO2 < 10 (%) represents the cutoff which predicts mortality in patients with IPF 
[2]. However, there were differences between the self-reported patient score on the 
questionnaire and the accelerometer’s results, depending on sex, age, education level, 
and body mass index (BMI). There is also a short form for this IPAQ [58].
4.6.2.2 Barthel index (BI)
Barthel index (BI) is based on basic physical activities for self-grooming, such as 
feeding, toilet use, bladder and bowel control, walking, dressing, bathing, brushing, 
or ascending and descending stairs. The total scores vary between 0 and 70; higher 
scores are associated with more active subjects. A change in the BI score after 1 
month of ET4 was arbitrarily classified as mild (a decrease of <10 points), moderate 
(10–15 points), or severe (>15 points) [59]. This index reflects the independence 
levels in PADL in IPF patients.
4.6.2.3 Baecke questionnaire
In Baecke questionnaire, the score reflects the level of energy consumed perform-
ing professional activities, sports, and entertainment and is also adapted for the 
elderly, obese, and Parkinson’s disease or cardiovascular patients [60].
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preferred method of being safer, with few movement artifacts, allowing a constant 
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In patients with advanced IPF, it is not always possible to perform cyclo-ergome-
try. Volitional fatigue or increased oxygen desaturation (SpO2 < 80%) is quickly 
reached, and dizziness or mental confusion may also occur within 10–12 min of 
effort [48]. The incremental exercise testing shows decreased aerobic capacity 
(V′O2peak ~ 62% from predicted) and reduced maximal achievable workload in 
ILD. Other changes in IPF patients such as inefficient ventilation, desaturation, gas 
exchange abnormalities, circulator, and skeletal muscle dysfunction are reported 
[2]. These changes provoke a downward spiral of hypoxia, limited exercise capacity, 
deconditioning, shallow breathing pattern, and pulmonary hypertension [48].
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Doppler-echocardiographic assessment of pulmonary artery systolic pressure 
should be assessed because a significant percentage of the IPF patients develop 
PH from early stages of the disease [10, 49]. It represents an important prognostic 
parameter [10, 49]. It usually replaces right heart catheterization, echocardiogra-
phy being a noninvasive and widely available tool for screening PH. A substantial 
desaturation during exercise or a disproportionate exercise limitation related to the 
degree of lung restriction will increase the suspicion of PH [7, 10].
4.5  Chest high-resolution computed tomography (HRCT) and  
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HRCT is the essential method to diagnose IPF. If the HRCT shows a pattern of 
usual interstitial pneumonia (UIP), this being the most characteristic to IPF, then 
its presence avoids invasive procedure such as lung biopsy. In the last few years, 
radiation-free techniques, such as the lung ultrasound, appear to be very sensitive 
in detecting fibrotic change or monitoring disease progression [50]. Imaging on 
HRCT is important and significant before a PRP, but its rehabilitation benefits are 
not assessed according to the initial findings.
4.6 Physical activity of daily living (PADL)
Physical activity of daily living (PADL) has a major impact on the quality of life 
and well-being of IPF patients and needs to be evaluated. PADL refers to volunteer 
movements that the patient performs at home, during professional or recreational 
activities that are energy-consuming. There is an inversely proportional relationship 
between PADL and sedentariness, reduced autonomy, disability, risk of hospital-
ization, and death [51]. Besides, the disease severity (dyspnea levels, SpO2 < 88%, 
DLCO < 40%, 6MWD, the extent of honeycombing on computed tomography, level 
of PH) was associated with lower physical activity among patients’ stable IPF [52].
4.6.1 PADL assessment
PADL assessment is performed either by direct observation (time and staff 
consuming because it is individually applied), energy expenditure (for research 
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calorimetry), questionnaires, and other devices with motion sensors (detect move-
ment and quantify PADL: pedometers, accelerometers, or physical activity monitors). 
The questionnaires are subjective methods of evaluating the effects of the symptoms 
on the patient’s daily activities and quality of life, and they are instruments that are 
used in evaluating PRP [53]. Achieving progress through training programs can 
motivate the patient to pursue an active lifestyle for as long as possible. Pedometers 
measure only the distance covered daily (10,000 steps/day for a healthy lifestyle in 
the general population), but the effort intensity is better quantified by accelerometers 
[54]. These are preferred in sedentary or disabled patients, being more sensitive to the 
detection and description of movements. Daily activity can be quantified using  
the activity monitor for at least seven consecutive days from awakening to bed [2]. 
The intensity of physical activity is evaluated on a scale of 1–5, depending on the 
energy expenditure, expressed in the metabolic equivalent task (METS) [55].
4.6.2 The questionnaires used in PADL evaluation
The questionnaires used in PADL evaluation for IPF are easy to apply, cheap, 
self-administered, validated (internal consistency and test-retest reliability) and 
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(4 METS), walking (3.3 METS), and sitting times. The total score is the sum of all 
types of activities (the number of minutes spent/day) multiplied by the level of 
energy (MET) and multiplied by the amount of time spent/week [(MET)-min/week] 
[55]. An active patient is considered to perform 600 METS-min/week (150 min/
week × 4METS moderate intensity activity) [54, 57]. IPAQ ≤ 417 (MET-min/week) 
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[2]. However, there were differences between the self-reported patient score on the 
questionnaire and the accelerometer’s results, depending on sex, age, education level, 
and body mass index (BMI). There is also a short form for this IPAQ [58].
4.6.2.2 Barthel index (BI)
Barthel index (BI) is based on basic physical activities for self-grooming, such as 
feeding, toilet use, bladder and bowel control, walking, dressing, bathing, brushing, 
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4.6.2.4  Stanford Seven-Day Physical Activity and Stanford Usual Activity 
questionnaires
Stanford Seven-Day Physical Activity and Stanford Usual Activity questionnaires are 
applied during an interview. The first one relates to the time spent doing physical 
activities and sleeping for the past 7 days. The second focuses on moderate and 
intense activities in the last 3 months [61].
The PADL level is positively influenced by supervised PRP that lasts at least 
7–8 weeks.
4.7 The quality of life questionnaire
The quality of life questionnaire has been developed and validated extrapolat-
ing those applied to COPD patients, given the lack of a specific disease-specific 
questionnaire for IPF [56].
4.7.1 St. George Respiratory Questionnaire (SGRQ )
St. George Respiratory Questionnaire and St. George Respiratory Questionnaire 
IPF-specific version (SGRQ-I) consist of 50 items referring to three categories: 
symptoms (8 items), activity (16 items), and impact (26 items) [36, 62, 63]. The 
total score varies from 0 to 100 points. Higher scores reveal a poorer health-related 
quality of life. SGRQ-I is reliable and comparable to the original SGRQ [64]. 
The SGRQ score was significantly correlated with FVC, FEV1 (%), 6MWD, and 
MRC. On the other hand, it did not show a significant correlation with DLCO or the 
level of desaturation at 6MWD, compared with CAT questionnaire [64].
4.7.2 Medical Outcomes Short-Form 36 (SF-36)
Medical Outcomes Short-Form 36 (SF-36) is a generic health-related quality of life 
questionnaire. It consists of eight multidimension items as general health, vitalities, 
physical functioning, physical role/problems, body pain, emotional roles/problems, 
social functioning, and mental health. Each of the dimensions is scored from 0 to 
100. Higher scores indicate a better health-related quality of life [65].
4.7.3 Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) can be applied in any dis-
abling chronic disease which leads to impairment of the psychic/emotional status of 
patients [66].
4.7.4 The Chronic Respiratory Disease Questionnaire (CRDQ )
The Chronic Respiratory Disease Questionnaire (CRDQ ) refers to dyspnea, fatiga-
bility, emotional impact, and self-control [67].
4.7.5 COPD assessment test (CAT)
COPD assessment test (CAT) was compared with other instruments applied to 
patients with IPF showing good psychometric properties among ILD patients. It is 
a self-administered questionnaire with eight items, each scored on a scale from 1 to 
5. There is a strong correlation between the CAT score and SGRQ score, indicating 
that it can be used for health-related quality of life assessment among patients with 
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IPF. Furthermore, CAT showed higher correlations with the physiological param-
eters than the SGRQ [67].
4.7.6 Tool to Assess Quality of Life in Idiopathic Fibrosis (ATAQ-IPF)
The Tool to Assess Quality of Life in Idiopathic Fibrosis (ATAQ-IPF) is an 
extensive, 74 items, a disease-specific instrument which measures the symptoms 
adequately, sleep, emotions, relationships, therapies, finances, and many others. 
The score correlates with disease severity, but future studies are needed [8].
4.7.7 King’s Brief Interstitial Lung Disease (K-BILD)
The King’s Brief Interstitial Lung Disease (K-BILD) questionnaire is a validated 
and responsive questionnaire for longitudinal assessment of ILD patients’ quality of 
life. A score change of 5 units is significant [68].
4.8 Muscle strength assessment
In muscle strength assessment, types of muscular impairment refer to mass 
(of different anatomical sites: biceps, triceps, etc.), strength, endurance, and 
performance [69]. Peripheral muscle force measurement may be important in 
PRP for understanding the impact of the disease on muscle mass, identifying 
patients at risk for physical impairment, and identifying those who can benefit 
from the prescription of an individualized resistance training program. Peripheral 
muscular dysfunction is a consequence of sedentary lifestyle, adopted by patients 
to avoid the symptoms and systemic effects of the disease (inflammation, 
hypoxemia, nutritional deficiency, corticosteroid side effects, electrolyte imbal-
ances). Commonly, quadriceps muscle dysfunction is used for the assessment of 
peripheral muscle strength. The tests that are used may be volitional (volitional 
techniques: identification of the maximum weight that the patient can lift, manual 
muscle testing with MRC scale, or by dynamometers: handheld and computer-
ized) or non-volitional (electrical stimulation of involuntary muscle contraction). 
The quadriceps maximal isometric voluntary contraction (QMVC) or predictive 
formulas (different equations for predicting quadriceps muscle strength) are 
described in literature, especially in studies on patients with COPD [70–72]. It is 
considered that patients have quadriceps muscle weakness if the value is <80% of 
predicted [73]. Knee extensor and elbow flexor strength could be measured with 
handheld dynamometer [69].
5.  Correlation between exercise tolerance, daily physical activity, and 
survival rate
a. 6MWD is an independent and discriminating predictor of mortality among 
patients with IPF, more accurate than FVC or DLCO [74, 75]:
• Basal value <250 m correlates with twofold increase in mortality, and if it is 
less than 207 m, patients have a more than fourfold greater mortality rate.
• A decrease of SpO2 < 88% during 6MWT is marker for increased mortality.
• A decrease in the walking distance within 6 months, greater than 50 m, 
would increase the mortality rate by three times.
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and responsive questionnaire for longitudinal assessment of ILD patients’ quality of 
life. A score change of 5 units is significant [68].
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considered that patients have quadriceps muscle weakness if the value is <80% of 
predicted [73]. Knee extensor and elbow flexor strength could be measured with 
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patients with IPF, more accurate than FVC or DLCO [74, 75]:
• Basal value <250 m correlates with twofold increase in mortality, and if it is 
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• A decrease in the walking distance within 6 months, greater than 50 m, 
would increase the mortality rate by three times.
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• A delayed heart rate return in 1 minute after the end of the 6MWD test and a 
variation <13 beats/min are strongly correlated with increased mortality.
b. Daily life physical activity level [76–78]:
• IPF patients are highly sedentary, having a daily physical activity level which 
is 35% lower than healthy sedentary controls.
• A value under 3.287 steps/day on accelerometers was associated with a 
poorer prognosis and three times higher risk for death for IPF patients.
• Peripheral muscle dysfunction related with a decrease of the physical activity 
level of daily life and exercise limitation is associated with reduced survival.
6. Types of pulmonary rehabilitation programs
PRP for IPF patients include several types of exercises, such as aerobic, resis-
tance, flexibility, balance training, and respiration technique. Their selection is 
based on the everyday lifestyle of each patient, preferences, disease severity, and 
the advantages of where the PRP will take place:
• “Inpatient” rehabilitation centers are a more appropriate method for the 
supervised exercise programs taking into account the symptoms and the risk of 
severe effort desaturation that may occur. The advantage is that during exercise 
sessions, patients are monitored for blood pressure, heart rate, SpO2, and symp-
toms, and the urgent treatment is available in case of complications [79, 80].
• “Outpatient”-based programs take place in the patient’s home under the 
assistance of a healthcare professional with expertise in exercise training.
• Home-based rehabilitation programs are an alternative to in-/outpatient pro-
grams. They are easy to perform, practical, cheap, and equally as effective, 
but unfortunately have a lower adherence rate and less improvements, so it is 
necessary to be supervised by phone calls [12, 78, 79, 81].
• Combined programs start in a specialized structure and continues at home 
after the patients are familiar with the type and intensity of exercise [83].
PRP includes physical training, patient education, and nutritional and psychological 
support [11]. Regardless of the type of PRP, it is beneficial to start it as soon as possible. 
We will keep in mind that the intensity of rehabilitation depends on the severity of 
functional impairment and is personalized to each patient. The physical therapist starts 
from breath retraining and relaxing postures which increase chest expansion and relax 
the inspiratory muscles (Jacobson, Schultz technique). They reinforce proper breathing 
patterns (diaphragm) and include exercises that tonify respiratory and skeletal muscle 
(endurance and resistance) in order to increase patients’ exercise capacity [2].
7. Types of exercises
The main objective of these training programs is teaching patients how to per-
form a series of structured and repetitive exercises that improve or maintain their 
physical fitness and decrease the respiratory discomfort [82].
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Educating patients about pursuing an active lifestyle even in the presence of IPF 
should be based on information about the types of exercises that can be performed, 
the regularity and duration of each session, and general instructions on how and 
what to follow through the program. During the follow-up with their patients, the 
doctor may be confronted with various questions, doubts, and anxiety from the 
patients. In the early stages of the disease, when the symptoms are not disabling, 
the patient’s motivation to follow a PRP is low. In advanced stages, the motivation 
is stronger because dyspnea limits exercise capacity and daily activities. According 
to several studies, the PRP with greatest benefits have 6–12 weeks programs, with 
2–3 sessions per week of 30 minutes duration. The exercise intensity is determined 
by patients’ walking speed on 6MWD (starting at 70–80%), or by the maximum 
workload on cycle ergometer test (50–60% or more of peak WR on CPET for 
cycling), maximum heart rate (up to 80%), or on the intensity of symptoms on the 
Borg scale (to reach a score above 5–7). The effort intensity can also be calculated 
from an average heart rate ± 5 beats, obtained in the last 3 minutes of the effort test 
[2, 21, 33, 84].
A comprehensive training program should include several types of exercises: 
breathing and balance exercises, aerobic, endurance, and flexibility (stretching)  
[2, 12, 20, 33, 84].
For increasing the endurance to effort, aerobic exercises can be used to train 
different muscle groups, depending on the patients’ preferences and physical 
resources. Aerobic exercises can include walking, stair climbing, treadmill walking, 
leg cycling, semi-recumbent cycling, or step climbing on an ergometer adapted for 
lower limbs [16]. Resistance training refers to the increase in muscle strength and 
can be achieved by performing repeated exercises for upper and lower limbs, arm 
raising, knee-extension, sit-to-stand, and strength training using elastic bands. 
In these types of exercises, the muscles work against an external force applied by 
a device from the physiotherapy room or against their own body weight. They can 
also use weights. These exercises are grouped in 2–4 sets, with 10–15 repetitions, 
followed by breaks of 45–60 s. Each set of exercises targets specific muscle groups 
[85]. These exercises are recommended due to the fact that IPF patients have 
reduced muscle mass, strength, and endurance, compared with healthy subjects. 
They develop atrophy and muscle weakness, especially in lower limbs [86, 87]. 
Stretching exercises are activities designed to maintain or increase joint mobility 
and muscle relaxation. Strength training targets major muscle groups of the upper 
and lower body. There is a wide range of exercises that could be applied by physio-
therapist [88]:
• Shoulder wheel
• Multiple movements of shoulder by changing his position as abduction, 
externally rotates the shoulder, flexion, and extension
• Sitting or standing biceps curls
• Mid-back rowing
• Shoulder flexion or extension
• Sitting or standing chest presses and triceps extensions
• Lower body exercises: standing hip abduction and extension
• Seated knee flexion and extension
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• Dumbbells shoulder press
• Dumbbells biceps curls
• Dumbbells arm extension
• Abdominal curl-ups
• Seated single leg hamstring stretch
• Standing quadriceps stretch
• Chest stretch
• Overhead reach stretch and wall cat stretch
For strength training there are three types of therapeutic bands that can be used: 
yellow, followed by red, and then green.
Respiratory muscle training or breathing exercises are extremely important, 
especially for patients with advanced disease, because they focus on diaphragm 
training, by teaching patients abdominal breathing techniques [79, 89].
There are no strictly standardized protocols for the PRP, allowing an experi-
enced physiotherapist to tailor the patient’s training structure in order to maximize 
the benefits.
The structure of a rehabilitation program should be seen as a multistage process:
• Firstly, the patient learns different types of exercise and different techniques, 
which can be divided into four categories (aerobic, endurance, flexibility, 
and breathing). Their intensity should be adapted to the severity of patient’s 
pulmonary impairment, typically 50–60% of the work peak rate for aerobic 
exercise and 70–80% of the walking speed in 6MWT for endurance exercises 
(bicycle, treadmill, walking). The program can start with breathing exercises 
or balance training, continued by aerobic exercise and resistance training. 
Exercises should primarily focus on increasing the strength and the muscle 
mass of the lower limbs and diaphragm. The interval technique can also be 
used, allowing the patient to rest between exercises. In patients who experi-
ence desaturations (SpO2 < 85%) during training, oxygen supplementation 
should be considered in order to maintain SpO2 above 88% [21]. During a 
program of 2–3 sessions/week, for 4–6 weeks, under the supervision of a 
physiotherapist, a patient can learn and become adequately trained to pass 
into the second phase.
• In the continuation and improvement phase, subjects can progressively 
increase both the frequency (3–4 times/week), duration, and intensity of 
the sessions. The aerobic program can be extended to 20–50 min and can be 
performed at an intensity of 60–85% of the work peak rate. The resistance 
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training can last between 20 and 30 min, with an intensity of 80–100% from 
the average walking speed obtained in the 6MWD test. Also, the programs 
recommend including 10–15 min of stretching and a minimum of 5 min of 
diaphragmatic or pursed lip breathing [90].
• The maintenance phase is important for preserving the benefits of a PRP, for 
decreasing the anxiety and depression level, and for increasing the quality of 
life. It is recommended to maintain the types and the intensity of exercises that 
will lead to a level of fatigue between 5 and 7 on the Borg scale.
Each patient should be reassessed at 3–6 months, in terms of effort tolerance, 
quality of life, disease progression, and response to pharmacological treatment.
In brief, a supervised training program for patients with IPF should recommend:
• 4–6 weeks, 2–3 sessions/week
• Aerobic effort 20–40 min
• Stretching 10–15 min
• Breathing techniques 5–10 min
• Adjusting the work intensity so it can be tolerable for the patient
• Oxygen supplementation for patients who desaturate (SpO2 85–88%)
• Intervals between exercises allowing better oxygenation
• Patient reassessment at the end of the 6 weeks
In a comprehensive PRP, patient’s education begins from understanding the 
patient’s needs and providing detailed information regarding the nature and 
expected course of the disease, solutions for symptoms management, benefits and 
side effects of treatments (depression, anxiety, obesity, diabetes, cardiovascular 
disease), the indication of oxygen supplementation, energy conservation tech-
niques, relaxation and recreation methods, stress management, coping techniques 
for anxiety and depression, smoking cessation, and solutions for the improvement 
of quality of life. Medical education sessions usually precede exercise training 
sessions. This will be individualized for each patient, ensuring optimal commu-
nication between the patient and the multidisciplinary team. Educational assess-
ment begins with the identification of difficulties, focusing on the change of the 
health-related behavior. Goals need to be established in the short, medium, and 
long term, to increase the patient’s motivation to follow a PRP. Educational therapy 
plays a role in the relief of symptoms and quality of life improvement, optimizing 
the benefits of a PRP [11].
Nutritional support refers to weight control and a balanced diet, with obesity or 
weight loss being associated with a poor prognosis. Adipose mass can be evaluated 
pre- and post-PR, using different skinfold calipers for the analysis of body composi-
tion by skinfold thickness measurements [91].
Due to the life-threatening course of the disease, the psychological support 
should be considered for each patient. The dialog among the patient, the patient’s 
family, and healthcare professionals can decrease the depression and anxiety in 
more than 50% of ILD patients [56].
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training can last between 20 and 30 min, with an intensity of 80–100% from 
the average walking speed obtained in the 6MWD test. Also, the programs 
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Each patient should be reassessed at 3–6 months, in terms of effort tolerance, 
quality of life, disease progression, and response to pharmacological treatment.
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• Aerobic effort 20–40 min
• Stretching 10–15 min
• Breathing techniques 5–10 min
• Adjusting the work intensity so it can be tolerable for the patient
• Oxygen supplementation for patients who desaturate (SpO2 85–88%)
• Intervals between exercises allowing better oxygenation
• Patient reassessment at the end of the 6 weeks
In a comprehensive PRP, patient’s education begins from understanding the 
patient’s needs and providing detailed information regarding the nature and 
expected course of the disease, solutions for symptoms management, benefits and 
side effects of treatments (depression, anxiety, obesity, diabetes, cardiovascular 
disease), the indication of oxygen supplementation, energy conservation tech-
niques, relaxation and recreation methods, stress management, coping techniques 
for anxiety and depression, smoking cessation, and solutions for the improvement 
of quality of life. Medical education sessions usually precede exercise training 
sessions. This will be individualized for each patient, ensuring optimal commu-
nication between the patient and the multidisciplinary team. Educational assess-
ment begins with the identification of difficulties, focusing on the change of the 
health-related behavior. Goals need to be established in the short, medium, and 
long term, to increase the patient’s motivation to follow a PRP. Educational therapy 
plays a role in the relief of symptoms and quality of life improvement, optimizing 
the benefits of a PRP [11].
Nutritional support refers to weight control and a balanced diet, with obesity or 
weight loss being associated with a poor prognosis. Adipose mass can be evaluated 
pre- and post-PR, using different skinfold calipers for the analysis of body composi-
tion by skinfold thickness measurements [91].
Due to the life-threatening course of the disease, the psychological support 
should be considered for each patient. The dialog among the patient, the patient’s 
family, and healthcare professionals can decrease the depression and anxiety in 
more than 50% of ILD patients [56].
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8. Results of the exercise training programs
Studies conducted support the beneficial effects of PR programs, at the end of 
which patients with IPF present [15, 19, 33]:
• Improvement in functional capacity
• Improvement in 6MWD results over SMD: 35.63 m (95% CI 16.02–55.23 m)
• Improvement in V′O2 peak at 6WMD 1.46 mL/kg/min−1 (95% CI 
0.54–2.39 mL/kg/min−1)
• Increased physical activity levels (IPAQ )
• Significant reduction in dyspnea: SMD −0.68 (95% CI −1.12 to −0.25)
• Improvement in wellness and health-related quality of life, especially for those 
with severe disease SMD 0.59 (95% CI 0.14–1.03)
• Increased muscular fitness
Quality of the evidence regarding the impact of PR programs in IPF patients 
after Dowman et al. [15]:
1. Change in 6-min walk distance—moderate ⊕⊕⊕⊝
2. Change in V′O2 peak uptake at cardiopulmonary exercise test—low ⊕⊕⊝⊝
3. Change in maximum ventilation cardiopulmonary exercise test—low ⊕⊕⊝⊝
4. Change in dyspnea score MMRC Dyspnea Scale—low ⊕⊕⊝⊝
5. Change in quality of life CRDQ (total score)—low ⊕⊕⊝⊝
6. Month survival—low ⊕⊕⊝⊝
A follow-up was performed 8–12 weeks after end of rehabilitation.
The review used the Grades of Recommendation, Assessment, Development 
and Evaluation (GRADE) to evaluate the study results: “Moderate quality: Further 
research is likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate. Low quality: Further research is very likely to 
have an important impact on our confidence in the estimate of effect and is likely to 
change the estimate” [15].
The increase in effort capacity is directly related to training frequency, three to 
five sessions per week being optimal and fewer than two sessions being unlikely to 
produce meaningful change [92].
It is considered that a PR has been beneficial if there has been an increase of 
more than 50 m at 6MWD test (31–81 m gained in PR in different clinical trials) and 
a minimum amount of physical activity at 200 METS-min/week [10 min × 4METS 
(moderate intensity in the IPAQ questionnaire) × 5 times/week. Longer programs 
and more frequent sessions (12 or more) appear to have a greater benefit; however 
these benefits can be lost after 3–6 months, if the training does not continue and 
patients fail to maintain an active lifestyle [11]. There are discrepancies in the 
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outcome of the studies, in patients who have undergone a pulmonary rehabilitation 
program, discussing the responder or non-responder label depending on whether 
or not the walking distance of 6MWD or V′O2 has improved. Non-responders are 
considered patients whose result of 6MWT did not rise above or equal to 30 m after 
PR (30 m considered as MCID) [93]. Also, the responders had FEV1 and TLC raised 
after the rehabilitation program and significantly increased V′O2 peak, carbon diox-
ide output (VCO2), and minute ventilation (VE) in the 6MWT post-PR test, while 
non-responders showed greater desaturation during exercise [93].
The different results of the studies can be explained by:
• Training programs with differences in intensity, duration, and type of admin-
istration (inpatient/outpatient, supervised/unsupervised)
• Small numbers of participants
• Methodological limitation: methods of randomization (uncontrolled studies or 
nonrandomized, unblinded study)
• Limitations of retrospective studies
• Different control batches (other types of ILD, sham, etc.)
• Patients entering PR at different stages of severity
• Inclusion and exclusion criteria
• No follow-up data after exercise training
• Different outcomes
9. Lung transplant pre- and post-rehabilitation programs
Conforming to the International Society for Heart and Lung Transplantation 
(ISHLT), this pulmonary transplantation is performed for a variety of advanced 
lung diseases, IPF, together with COPD, being the most common indication. 
However, in posttransplant survival, IPF is associated with the worst prognosis. For 
patients with IPF, transplantation and supplemental oxygen were the only treat-
ments strongly recommended by the latest ATS consensus document. A transplant 
discussion is recommended from the moment the positive diagnosis is confirmed 
due to low survival [94, 95].
Medical and surgical interventions in transplants have progressed in the last 
few years. All of these lead to a changing demographic of patients undergoing lung 
transplantation, including older subjects with multiple comorbidities, respiratory 
failure, and even those who require bridging to transplantation [95]. To ensure a 
high rate of posttransplant survival, both in the short and long term, these patients 
must be physically and psychologically trained for this complex process. PRP 
plays an essential role in pulmonary transplantation, both by optimizing physical 
function prior to surgical intervention and by facilitating posttransplant recovery. 
Although these PRP are mandatory in most transplant centers, to date there is no 
international pulmonary rehabilitation guideline for this patient category [95].
Physiotherapists working with lung transplant candidates and recipients need 
expertise both in general exercise training principles and in pre- and posttransplant 
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international pulmonary rehabilitation guideline for this patient category [95].
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expertise both in general exercise training principles and in pre- and posttransplant 
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rehabilitation, complications, oxygen titration, and side effects of medications. 
They should be able to adapt exercise programs according to the lung function 
changes and according to episodic illnesses (exacerbation) [95, 96].
Prior to transplant, patients should attend PRP and benefit from exercise 
training, aerobic, resistance, and flexibility, with or without oxygen support, in the 
tolerance limit. In early posttransplant period, mobility is advised even in ICU and 
in acute hospitalization, for the progression to independent function (transfers, 
walking, self-care, climbing stairs). In the next phase (1–6 month), they should 
gradually perform balance training, aerobic, resistance, and flexibility exercises, 
as tolerated. Oxygen can be supplemented to support exercise. In the long term 
(>6 months), patients should be included in home and community PR programs for 
maintaining and improving the benefits of this intervention [96]. All these aspects 
are the premises for a better prognosis and lower costs for the healthcare system.
10. General recommendations
• A multidisciplinary team that includes a respiratory specialist and a clinical 
psychotherapist should manage and supervise the inclusion in a PR program 
of patients with IPF and the structure and monitoring of the patients’ exercise 
training sessions.
• In patients with severe IPF, it is preferred that programs are held in the hospi-
tal. In case programs are held at patient’s home, then high-intensity exercises 
that could lead to desaturation and worsening of symptoms should be avoided.
• For long-term benefits, three to five sessions per week for a minimum of 
6 weeks are optimal, less than two sessions being unlikely to produce signifi-
cant change [92].
• Initially, the interval training method is preferred, and in time, the duration of 
the exercises can be increased. A break and rest are mandatory when excessive 
fatigue and dyspnea appear [12].
• The overall load increases gradually according to patient’s tolerance, the 
intensity of effort being adjusted to patients’ fatigue tolerance.
• Additional oxygen can be used during exercise as it allows for an increased 
endurance and intensity of exercise levels [1].
• Factors such as self-motivation, fear of adverse events, or comprehension may 
affect the ability to tolerate exercise training.
11. Conclusions
The pulmonary rehabilitation has become a clear indication as a non-phar-
macological therapy for patients diagnosed with IPF. The benefits of pulmonary 
rehabilitation programs are reduced respiratory symptoms, especially dyspnea, and 
increased exercise tolerance and level of physical activity. All these lead to a lower 
level of anxiety and depression and therefore increased quality of life. These ben-
efits are sustained in short term, 3–6 months. They can be maintained for a longer 
period if the patient has a responsible behavior and an active lifestyle.
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